<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int Immunopharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Int. Immunopharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>International Immunopharmacology</journal-title></journal-title-group><issn pub-type="ppub">1567-5769</issn><issn pub-type="epub">1878-1705</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7301105</article-id><article-id pub-id-type="pmcid-ver">PMC7301105.1</article-id><article-id pub-id-type="pmcaid">7301105</article-id><article-id pub-id-type="pmcaiid">7301105</article-id><article-id pub-id-type="pmid">32585611</article-id><article-id pub-id-type="doi">10.1016/j.intimp.2020.106717</article-id><article-id pub-id-type="publisher-id">S1567-5769(20)31386-2</article-id><article-id pub-id-type="publisher-id">106717</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Potential adjuvants for the development of a SARS-CoV-2 vaccine based on experimental results from similar coronaviruses</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name name-style="western"><surname>Gupta</surname><given-names initials="T">Tania</given-names></name><email>dr.tania603@gmail.com</email><xref rid="af005" ref-type="aff">a</xref><xref rid="fn1" ref-type="fn">1</xref><xref rid="cor1" ref-type="corresp">&#8270;</xref></contrib><contrib contrib-type="author" id="au010"><name name-style="western"><surname>Gupta</surname><given-names initials="SK">Shishir K</given-names></name><xref rid="af010" ref-type="aff">b</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><aff id="af005"><label>a</label>Dr GC Negi College of Veterinary and Animal Sciences, Palampur 176062, Himachal Pradesh, India</aff><aff id="af010"><label>b</label>CSIR-Central Drug Research Institute, Lucknow 226031, Uttar Pradesh, India</aff></contrib-group><author-notes><corresp id="cor1"><label>&#8270;</label>Corresponding author. <email>dr.tania603@gmail.com</email></corresp><fn id="fn1"><label>1</label><p id="np005">Authors contributed equally.</p></fn></author-notes><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>18</day><month>6</month><year>2020</year></pub-date><volume>86</volume><issue-id pub-id-type="pmc-issue-id">359767</issue-id><fpage>106717</fpage><lpage>106717</lpage><history><date date-type="received"><day>2</day><month>5</month><year>2020</year></date><date date-type="rev-recd"><day>3</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>6</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>06</month><year>2020</year></date></event><event event-type="pmc-live"><date><day>18</day><month>06</month><year>2020</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-18 15:25:35.683"><day>18</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2020 Elsevier B.V. All rights reserved.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Elsevier B.V.</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract abstract-type="author-highlights" id="ab005"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="o0005"><label>&#8226;</label><p id="p0005">Discusses the importance of adjuvants in the development of a vaccine against SARS-CoV-2.</p></list-item><list-item id="o0010"><label>&#8226;</label><p id="p0010">Summarizes the results of clinical vaccine studies on similar coronaviruses with various adjuvants.</p></list-item><list-item id="o0015"><label>&#8226;</label><p id="p0015">Discusses the current progress in the development of adjuvanted vaccines against COVID-19.</p></list-item></list></p></abstract><abstract id="ab010"><p>The extensive efforts around the globe are being made to develop a suitable vaccine against COVID-19 (Coronavirus Disease-19) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2). An effective vaccine should be able to induce high titers of neutralizing antibodies to prevent the virus from attaching to the host cell receptors. However, to elicit the protective levels of antibodies, a vaccine may require multiple doses or assistance from other immunostimulatory molecules. Further, the vaccine should be able to induce protective levels of antibodies rapidly with the least amount of antigen used. This decreases the cost of a vaccine and makes it affordable. As the pandemic has hit most countries across the globe, there will be an overwhelming demand for the vaccine in a quick time. Incorporating a suitable adjuvant in a SARS-CoV-2 vaccine may address these requirements. This review paper will discuss the experimental results of the adjuvanted vaccine studies with similar coronaviruses (CoVs) which might be useful to select an appropriate adjuvant for a vaccine against rapidly emerging&#160;SARS-CoV-2. We also discuss the current progress in the development of adjuvanted vaccines against the disease.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>COVID-19</kwd><kwd>SARS</kwd><kwd>SARS-CoV-2</kwd><kwd>Adjuvant</kwd><kwd>Vaccine</kwd><kwd>Coronavirus</kwd><kwd>MERS</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0020">The SARS-CoV-2, a member of family Coronaviridae and the causative agent of COVID-19 disease, has spread rapidly around the globe since the first outbreak in Wuhan, China in December 2019. The World Health Organization (WHO) declared the outbreak as the sixth public health emergency of international concern on 30th January 2020 <xref rid="b0005" ref-type="bibr">[1]</xref>, <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>. Despite the tremendous efforts to contain the virus, its spread is ongoing. Though the majority of cases resolve spontaneously, some develop various fatal complications, including organ failure, septic shock, pulmonary edema, severe pneumonia, and Acute Respiratory Distress Syndrome (ARDS) <xref rid="b0025" ref-type="bibr">[5]</xref>, <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>. Before the current pandemic, highly pathogenic CoVs have hit the world as severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome (MERS) coronavirus in 2012. The SARS-CoV-2 has been identified as a &#946;-coronavirus, and like SARS-CoV, it binds to angiotensin-converting enzyme 2 (ACE2) receptors <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>. Recent data on genome sequencing of SARS-CoV-2 revealed that it shares approximately 79.6% similarity with SARS-CoV at the nucleotide level <xref rid="b0045" ref-type="bibr">[9]</xref>, which varies between the different genes. SARS-CoV-2 contains a linear single-stranded positive-sense RNA as genetic material that encodes for the spike (S), envelop (E), membrane (M), and nucleocapsid (N) proteins <xref rid="b0050" ref-type="bibr">[10]</xref>. The spike protein that binds to host cell receptors shares about 72% nucleotide similarity between these two <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>, <xref rid="b0065" ref-type="bibr">[13]</xref>. The S protein consists of two subunits S1 and S2, S1 interacts with the surface receptor and S2 helps in the fusion of viral and cellular membranes, and subsequent entry of the virus into the host cells. Different coronaviruses, depending upon the viral species, use different receptor binding domains (RBD) present on the S1 subunit to interact with host cell receptors <xref rid="b0040" ref-type="bibr">[8]</xref>, <xref rid="b0045" ref-type="bibr">[9]</xref>. While RBD of MERS-CoV recognizes non-acetylated sialoside attachment receptors (human dipeptidyl peptidase 4) <xref rid="b0070" ref-type="bibr">[14]</xref>, <xref rid="b0075" ref-type="bibr">[15]</xref>, SARS-CoV interacts with ACE2 receptors <xref rid="b0080" ref-type="bibr">[16]</xref>. However, SARS-CoV-2, as compared to SARS-CoV, contains different amino acids (five amino acids out of six are mutated) composition in its RBD that are crucial for receptor binding (ACE2) with high affinity <xref rid="b0085" ref-type="bibr">[17]</xref>, and has a functional polybasic furin site at S1-S2 boundary that may have a role in defining the viral infectivity and host range <xref rid="b0090" ref-type="bibr">[18]</xref>, <xref rid="b0095" ref-type="bibr">[19]</xref>. The furin cleavage site is not reported in SARS-CoV, and its fusion to membrane involves either direct receptor-mediated fusion or receptor-mediated endocytosis <xref rid="b0100" ref-type="bibr">[20]</xref>. The high-affinity binding of SARS-CoV-2 with ACE2 receptor along with the presence of furin and TMPRSS2 (at S2&#8242;) cleavage sites explain its rapid spread and strong ability for human to human transmission <xref rid="b0105" ref-type="bibr">[21]</xref>.</p><p id="p0025">Currently, there is no specific anti-viral medicine or vaccine available for the disease; however, many studies and clinical trials are being undertaken to assess the efficacy and safety of various drugs and vaccine candidates <xref rid="b0110" ref-type="bibr">[22]</xref>. As SARS-CoV-2 share significant similarities with SARS and MERS coronaviruses and use similar spike protein for receptor binding, the key information from the past vaccine studies with such similar viruses, may help accelerate the development of an effective therapy/vaccine against COVID-19.</p><p id="p0030">Vaccine candidates against SARS-CoV have been tested in many studies and include inactivated whole virus vaccine, recombinant spike (S) protein preparations, virus-like particles (VLPs), plasmid DNA, and several viral vectors containing genes for SARS-CoV proteins [<xref rid="f0005" ref-type="fig">Fig. 1</xref>
] <xref rid="b0115" ref-type="bibr">[23]</xref>, <xref rid="b0120" ref-type="bibr">[24]</xref>, <xref rid="b0125" ref-type="bibr">[25]</xref>. Many of such vaccine candidates efficiently induced the production of neutralizing antibodies. Such antibodies target the spike protein of the coronavirus, so it cannot bind to its cellular receptor, and, consequently, it cannot enter the cell. However, there are a few basic constraints to vaccine development. The key factor in vaccine design is ensuring the efficacy of the vaccine while reducing the potential risks associated with it. The inactivated virus vaccine may not elicit an ideal immune response to confer protective immunity and may require multiple booster doses. Similarly, new generation vaccines that contain recombinant viral proteins, need help from immunostimulatory molecules <xref rid="b0130" ref-type="bibr">[26]</xref>, <xref rid="b0135" ref-type="bibr">[27]</xref>. Further, as with other RNA viruses, these CoVs go through frequent recombination; therefore, a live attenuated vaccine carries the inherent risk of reversal to a virulent form and may pose a severe threat to human lives. Ideally, a vaccine against a highly pathogenic virus, including CoVs should be able to generate a protective antibody response to the minimum antigen dose in a quick time with no adverse reactions. The COVID-19 is spreading globally and infecting a large number of people due to the lack of any prophylactic measure. The demand for the vaccine, once available, will be overwhelming, and therefore; highly desirable for a potential vaccine to be able to induce immunity in a short time with the minimum quantity of the antigen required. This will make it affordable and help meet the high global demands <xref rid="b0140" ref-type="bibr">[28]</xref>, <xref rid="b0145" ref-type="bibr">[29]</xref>. Most of the above issues may be resolved by incorporating a suitable adjuvant in vaccine preparations, which will not only help in eliciting a robust immune response but also possibly reduce the antigen quantity and the need for multiple doses of vaccine. Thus, the selection of an effective adjuvant becomes crucial for the development of an adjuvanted vaccine against COVID-19. The past vaccine studies on similar CoVs with various adjuvant combinations may provide key information and help in picking adjuvants which possess a good safety profile and efficacy. Therefore, in this review, we discuss the past adjuvanted vaccine studies and their outcomes, with similar CoVs which might be useful in developing an adjuvanted vaccine against COVID-19. Further, we briefly discuss the current progress in the development of adjuvanted vaccines against COVID-19.<fig id="f0005" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>As SARS-CoV-2 is highly similar to SARS-CoV at the genomic level, the outcomes of the past vaccine studies may expedite the development of a vaccine against COVID-19.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p></sec><sec id="s0010"><label>2</label><title>Adjuvants</title><sec id="s0015"><label>2.1</label><title>Aluminum hydroxide</title><p id="p0035">Aluminum hydroxide (alum) is the most commonly used agent as an adjuvant. The mechanism of its adjuvant action is complex and, so far, multiple hypotheses have been put forward to explain its mode of action <xref rid="b0760" ref-type="bibr">[152]</xref>. It has been shown to act by depot formation at the site of injection allowing for a slow release of antigen. This prolongs the interaction time between antigen and antigen-presenting cells (APCs). Further, it converts soluble antigens into particulate forms which are readily phagocytosed <xref rid="b0150" ref-type="bibr">[30]</xref>. At the cellular level, aluminum hydroxide directly stimulates monocytes to produce pro-inflammatory cytokines activating T cells. Activated Th2 cells release IL-4, which in turn can induce an increase in the expression of MHC class II molecules on monocytes <xref rid="b0155" ref-type="bibr">[31]</xref>. Alum has been approved as an adjuvant in multiple licensed vaccines for human use in the majority of the countries worldwide (<xref rid="t0005" ref-type="table">Table. 1</xref>
) <xref rid="b0160" ref-type="bibr">[32]</xref>, <xref rid="b0165" ref-type="bibr">[33]</xref>. Mice immunized with UV-inactivated SARS-CoV particles elicited a high level of humoral immunity that resulted in the generation of long-term antibody-secreting and memory B cells. Further, the addition of alum to the vaccine formula significantly augmented serum IgG and reached a level similar to that found in hyper-immunized mice <xref rid="b0170" ref-type="bibr">[34]</xref>. The antibodies elicited in mice recognized both the spike and nucleocapsid proteins and neutralized the virus. Tang et al <xref rid="b0175" ref-type="bibr">[35]</xref> using inactivated SARS-CoV with or without alum adjuvant in female BALB/c mice, demonstrated that the antibodies to SARS-CoV were induced by the adjuvanted vaccine were higher than those without adjuvant. In non-human primates (NHPs), purified inactivated SARS-CoV vaccine with and without alum when administered in Cynomolgus and Rhesus macaques, protected the monkeys from the challenge of SARS-CoV without causing any adverse reactions (<xref rid="t0010" ref-type="table">Table. 2</xref>
). Similarly, an inactivated MERS-CoV vaccine adjuvanted with alum plus CpG protected the Ad5-hDPP4 transduced mice <xref rid="b0180" ref-type="bibr">[36]</xref>, <xref rid="b0185" ref-type="bibr">[37]</xref>, <xref rid="b0190" ref-type="bibr">[38]</xref>. Though studies reported the safe use of inactivated viral particles as a vaccine, a few reports observed the occurrence of antibody-dependent enhancement of disease (ADE) and immunopathological changes in the lungs in response to live viral challenge after immunization with inactivated virus vaccine <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>, <xref rid="b0205" ref-type="bibr">[41]</xref>. Further studies attributed the occurrence of immunopathological changes or ADE to the presence of anti-N antibodies or non-neutralizing antibodies, antibody isotype, low affinity, or suboptimal levels of neutralizing antibodies induced by immunization with an inactivated virus vaccine alone or with alum <xref rid="b0205" ref-type="bibr">[41]</xref>, <xref rid="b0210" ref-type="bibr">[42]</xref>, <xref rid="b0215" ref-type="bibr">[43]</xref>, <xref rid="b0220" ref-type="bibr">[44]</xref>. Inclusion of an adjuvant that favors a predominantly Th1 response to the whole virus inactivated vaccine may alleviate the issue of Th2-type immunopathology <xref rid="b0190" ref-type="bibr">[38]</xref>, <xref rid="b0205" ref-type="bibr">[41]</xref>, <xref rid="b0225" ref-type="bibr">[45]</xref>. These points must be taken into consideration while proceeding with the development of the adjuvanted COVID-19 vaccine using the inactivated virus.<table-wrap position="float" id="t0005" orientation="portrait"><label>Table 1</label><caption><p>Common vaccine adjuvants.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr. No.</th><th colspan="1" rowspan="1">Adjuvants</th><th colspan="1" rowspan="1">Possible adverse reactions</th><th colspan="1" rowspan="1">Status/Approval</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">Granulomas, allergenicity, potential neurotoxicity</td><td colspan="1" rowspan="1">Approved for many human vaccines such as Hepatitis A, hepatitis B, Haemophilus influenza type b (Hib) diphtheria&#8211;tetanus&#8211;pertussis (DTaP, Tdap), etc.</td><td colspan="1" rowspan="1"><xref rid="b0160" ref-type="bibr">[32]</xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">MF59&#8482;</td><td colspan="1" rowspan="1">Injection site pain, local tissue damage inflammatory reactions, sterile granuloma ulceration</td><td colspan="1" rowspan="1">Approved for the flu vaccine (FLUAD&#174;)</td><td colspan="1" rowspan="1"><xref rid="b0625" ref-type="bibr">[125]</xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">AS01/AS03/AS04</td><td colspan="1" rowspan="1">Injection site pain, local tissue damage inflammatory reactions, sterile granuloma ulceration</td><td colspan="1" rowspan="1">Approved for RZV,&#160;Shingrix, influenza, and Cervarix &#8211; HPV vaccines, respectively</td><td colspan="1" rowspan="1"><xref rid="b0630" ref-type="bibr">[126]</xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Montanide ISA-51</td><td colspan="1" rowspan="1">Injection site pain, local tissue damage inflammatory reactions, sterile granuloma ulceration</td><td colspan="1" rowspan="1">Approved for use in the lung cancer vaccine (CIMAvax EGF) in Cuba</td><td colspan="1" rowspan="1"><xref rid="b0630" ref-type="bibr">[126]</xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">Delta inulin</td><td colspan="1" rowspan="1">Safe, mild local reactions</td><td colspan="1" rowspan="1">Clinical trial phase-1 for seasonal influenza and hepatitis B</td><td colspan="1" rowspan="1"><xref rid="b0420" ref-type="bibr">[84]</xref>, <xref rid="b0635" ref-type="bibr">[127]</xref>, <xref rid="b0640" ref-type="bibr">[128]</xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">TLR3</td><td colspan="1" rowspan="1">(Poly-ICLC): Transient neutropenia, mild injection site reactions, erythema and induration at the site of injection, transient flu-like symptoms, such as malaise, headache, fever, and chills</td><td colspan="1" rowspan="1">Clinical trial phase-I/II for various cancers and HIV vaccines</td><td colspan="1" rowspan="1"><xref rid="b0645" ref-type="bibr">[129]</xref>, <xref rid="b0650" ref-type="bibr">[130]</xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">TLR4</td><td colspan="1" rowspan="1">MPL: Mild reactions in formulationsGLA: mild reactions including erythematous reactions, tenderness, and fever</td><td colspan="1" rowspan="1">MPL: Approved for use in adjuvant systems (AS)GLA: In various phases of clinical trials</td><td colspan="1" rowspan="1"><xref rid="b0655" ref-type="bibr">[131]</xref>, <xref rid="b0660" ref-type="bibr">[132]</xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">TLR9</td><td colspan="1" rowspan="1">Injection-site reactions or systemic flu-like symptoms may trigger autoimmune disease or inflammation</td><td colspan="1" rowspan="1">CpG1018 approved for a Hepatitis B vaccine (HEPLISAV-B)</td><td colspan="1" rowspan="1"><xref rid="b0655" ref-type="bibr">[131]</xref>, <xref rid="b0665" ref-type="bibr">[133]</xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">TLR7/8</td><td colspan="1" rowspan="1">Resiquimod (oral): Systemic cytokine induction, including fever, headache, shivering, and&#160;lymphopeniaImiquimod (topical): Mild adverse reactions</td><td colspan="1" rowspan="1">Imiquimod R837 is approved for topical application in basal and squamous cell&#160;carcinomas</td><td colspan="1" rowspan="1"><xref rid="b0655" ref-type="bibr">[131]</xref>, <xref rid="b0670" ref-type="bibr">[134]</xref></td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">rOv-ASP-1</td><td colspan="1" rowspan="1">No adverse reactions in NHPs</td><td colspan="1" rowspan="1">Pre-clinical stage vaccine trials against influenza and HIV-1</td><td colspan="1" rowspan="1"><xref rid="b0510" ref-type="bibr">[102]</xref>, <xref rid="b0525" ref-type="bibr">[105]</xref>, <xref rid="b0675" ref-type="bibr">[135]</xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Protollin</td><td colspan="1" rowspan="1">Rhinorrhoea and mild nasal congestion, malaise, myalgia, and headache</td><td colspan="1" rowspan="1">Pre-clinical stage vaccine trials against influenza and SARS, measles, respiratory syncytial virus (RSV)</td><td colspan="1" rowspan="1"><xref rid="b0550" ref-type="bibr">[110]</xref>, <xref rid="b0680" ref-type="bibr">[136]</xref>, <xref rid="b0685" ref-type="bibr">[137]</xref>, <xref rid="b0690" ref-type="bibr">[138]</xref></td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">CoVaccine HT&#8482;</td><td colspan="1" rowspan="1">No local or systemic adverse events were detected in macaques, temporary elevations in neutrophil count and drop in free serum iron in Rhesus monkeys</td><td colspan="1" rowspan="1">Phase 1 clinical trials</td><td colspan="1" rowspan="1">[<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01015703">NCT01015703</ext-link>] <xref rid="b0695" ref-type="bibr">[139]</xref>, <xref rid="b0700" ref-type="bibr">[140]</xref></td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">Matrix M&#8482;</td><td colspan="1" rowspan="1">Local reaction including pain, tenderness, swelling, and erythema at the injection site. The mild systemic reactions such as headache, myalgia, and fatigue</td><td colspan="1" rowspan="1">Phase I clinical trial for H5N1 vaccine</td><td colspan="1" rowspan="1"><xref rid="b0705" ref-type="bibr">[141]</xref>, <xref rid="b0710" ref-type="bibr">[142]</xref></td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0010" orientation="portrait"><label>Table 2</label><caption><p>Important vaccine studies on SARS-CoV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr. No.</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Vaccine candidate</th><th colspan="1" rowspan="1">Animal model</th><th colspan="1" rowspan="1">Results</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">Inactivated SARS-CoV vaccine (BJ-01 strain)</td><td colspan="1" rowspan="1">Cynomolgus macaques</td><td colspan="1" rowspan="1">Vaccine induced high levels of neutralizing antibodies. Prevented the replication of SARS-CoV in monkeys Protected monkeys on live viral challenge. ADE was not observed</td><td colspan="1" rowspan="1"><xref rid="b0180" ref-type="bibr">[36]</xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">Double-inactivated SARS-CoV</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">SARS-CoV vaccine induced antibody and protection against infection with SARS-CoV. On challenge, Th2-type immunopathology was observed</td><td colspan="1" rowspan="1"><xref rid="b0200" ref-type="bibr">[40]</xref>, <xref rid="b0205" ref-type="bibr">[41]</xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">A recombinant SARS-CoV spike (S) vaccine (truncated version)</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Alum adjuvanted group produced significantly enhanced immune responses. Fewer doses and a lower concentration of vaccine induced higher viral neutralizing antibodies in adjuvanted groups</td><td colspan="1" rowspan="1"><xref rid="b0230" ref-type="bibr">[46]</xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">Chimeric VLPs carrying SARS-CoV S protein</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Induced high levels of SCoV-specific neutralizing antibodies. Protected the animals on live viral challengeThe study did not observe ADE</td><td colspan="1" rowspan="1"><xref rid="b0240" ref-type="bibr">[48]</xref>, <xref rid="b0245" ref-type="bibr">[49]</xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">Alum/Matrix-M&#8482;</td><td colspan="1" rowspan="1">SARS-CoV S and MERS-CoV S nanoparticles vaccine</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Alum adjuvanted both vaccines SARS-CoV and MERS-CoV induced high neutralizing antibody titers; however, Matrix-M&#8482; induced higher antibody levels than alum</td><td colspan="1" rowspan="1"><xref rid="b0250" ref-type="bibr">[50]</xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">MF59</td><td colspan="1" rowspan="1">Inactivated SARS-CoV vaccine</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Elicited high titers of neutralizing antibodies, and protected the mice from lethal viral challenge</td><td colspan="1" rowspan="1"><xref rid="b0300" ref-type="bibr">[60]</xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">Montanide ISA-51/CpG</td><td colspan="1" rowspan="1">SARS-CoV S protein peptides</td><td colspan="1" rowspan="1">Mice, guinea pigs rabbits</td><td colspan="1" rowspan="1">Antibodies inhibited SARS/HIV pseudovirus entry into HepG2 cells, One of the peptides (D2) tested could induce neutralizing antibodies as well as T cell response</td><td colspan="1" rowspan="1"><xref rid="b0360" ref-type="bibr">[72]</xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Montanide ISA-51/CpG</td><td colspan="1" rowspan="1">DNA vaccine coding N protein of SARS-CoV/Recombinant N protein</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Mice receiving DNA vaccine plus recombinant N protein along with adjuvants produced high IgG antibodies specific to N protein</td><td colspan="1" rowspan="1"><xref rid="b0355" ref-type="bibr">[71]</xref>, <xref rid="b0365" ref-type="bibr">[73]</xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">AS01/AS03</td><td colspan="1" rowspan="1">Inactivated whole SARS-CoV vaccine</td><td colspan="1" rowspan="1">Mice/Hamster</td><td colspan="1" rowspan="1">The adjuvanted vaccine provided better protectionThe AS01 adjuvanted vaccine induced higher neutralizing antibodies than AS03. The ADE of disease was not observed in hamster</td><td colspan="1" rowspan="1"><xref rid="b0410" ref-type="bibr">[82]</xref></td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">Delta inulin/Alum/CpG</td><td colspan="1" rowspan="1">Recombinant SARS-CoV spike protein / Inactivated whole SARS-CoV</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">The adjuvanted vaccines induced a high concentration of neutralizing antibodies and protected the animals from wild viral challenge. The alum adjuvanted vaccine triggered lung eosinophilic immunopathology which was not observed with delta inulin adjuvanted vaccine</td><td colspan="1" rowspan="1"><xref rid="b0225" ref-type="bibr">[45]</xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">LPS/poly(U)/poly(I&#183;C)</td><td colspan="1" rowspan="1">Whole UV-inactivated SARS-CoV</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">The inactivated vaccine with alum induced lung eosinophilic immunopathology; However, the addition of TLR ligands reduced lung eosinophilic immunopathology significantly</td><td colspan="1" rowspan="1"><xref rid="b0455" ref-type="bibr">[91]</xref></td></tr><tr><td colspan="1" rowspan="1">12</td><td colspan="1" rowspan="1">CpG</td><td colspan="1" rowspan="1">Inactivated SARS-CoV vaccine</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">The adjuvanted vaccine produced serum neutralizing antibodies as well as specific IgA in tracheal-lung wash fluids</td><td colspan="1" rowspan="1"><xref rid="b0465" ref-type="bibr">[93]</xref>, <xref rid="b0470" ref-type="bibr">[94]</xref></td></tr><tr><td colspan="1" rowspan="1">13</td><td colspan="1" rowspan="1">PIKA (TLR3)</td><td colspan="1" rowspan="1">Inactivated SARS-CoV vaccine</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">The adjuvanted vaccine elicited both systemic and mucosal neutralizing humoral responses via both the routes</td><td colspan="1" rowspan="1"><xref rid="b0475" ref-type="bibr">[95]</xref></td></tr><tr><td colspan="1" rowspan="1">14</td><td colspan="1" rowspan="1">CpG ODN/ poly(I:C)/ R848</td><td colspan="1" rowspan="1">HLA-A*0201 restricted SARS-CoV S peptides</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">The vaccine alone elicited antigen-specific CD8<sup>+</sup> T cells responses which were further augmented by CpG adjuvant. The elicited CD8<sup>+</sup> T cells carried the memory T cell phenotype</td><td colspan="1" rowspan="1"><xref rid="b0485" ref-type="bibr">[97]</xref></td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">CpG/Alum</td><td colspan="1" rowspan="1">SARS-CoV RBD vaccine</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">The alum adjuvanted vaccine induced high anti-RBD neutralizing antibodies; however, the addition of CpG caused the production of IgG2a antibodies and high IFN-&#947; secretion. The studies demonstrated carbohydrate to be important for immunogenicity of peptide</td><td colspan="1" rowspan="1"><xref rid="b0490" ref-type="bibr">[98]</xref></td></tr><tr><td colspan="1" rowspan="1">16</td><td colspan="1" rowspan="1">rOv-ASP-1</td><td colspan="1" rowspan="1">SARS-CoV RBD protein vaccine</td><td colspan="1" rowspan="1">Mice/ Rhesus macaques</td><td colspan="1" rowspan="1">The adjuvanted vaccine in mice induced Anti-RBD specific neutralizing antibodies; however, also produced anti-ASP-1 antibodies though it did not affect its adjuvanticityThe vaccine also produced significant neutralizing antibodies in NHPs but did not produce much antibodies against protein adjuvant</td><td colspan="1" rowspan="1"><xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0510" ref-type="bibr">[102]</xref></td></tr><tr><td colspan="1" rowspan="1">17</td><td colspan="1" rowspan="1">rOv-ASP-1</td><td colspan="1" rowspan="1">SARS-CoV S peptide vaccine</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Demonstrated that rOv-ASP-1 was a better adjuvant than alum or MPL&#160;+&#160;TDM. It enhanced production Th-1 associated IgG2a isotype. The adjuvanted vaccine produced high antibody responses to SARS peptide</td><td colspan="1" rowspan="1"><xref rid="b0525" ref-type="bibr">[105]</xref></td></tr><tr><td colspan="1" rowspan="1">18</td><td colspan="1" rowspan="1">Protollin</td><td colspan="1" rowspan="1">SARS-CoV spike protein</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">The adjuvanted vaccine elicited high levels of antigen-specific IgG in serum. The antibodies were neutralizing in nature. It also elicited antigen-specific IgA levels. The vaccine protected mice on the viral challenge.</td><td colspan="1" rowspan="1"><xref rid="b0560" ref-type="bibr">[112]</xref></td></tr></tbody></table></table-wrap></p><p id="p0040">Recombinant subunit or newer generation vaccines have drawn a lot of attention in recent times. A truncated version of SARS-CoV S glycoprotein, containing only the ectodomain that was cloned and expressed in a serum-free insect cell line, when injected into the mice along with alum, induced significantly higher levels of viral neutralizing antibodies with fewer doses and a lower concentration of S glycoprotein <xref rid="b0230" ref-type="bibr">[46]</xref>, <xref rid="b0235" ref-type="bibr">[47]</xref>. Full-length recombinant spike protein plus alum preparations were as immunogenic as Virus-like particles (VLPs) containing the spike protein and the influenza M1 protein, both vaccines resulted in the induction of strong neutralizing antibodies that protected against lethal challenge in a mouse model <xref rid="b0240" ref-type="bibr">[48]</xref>. Chimeric VLPs consist of SARS-CoV S protein and E, M, and N proteins of mouse hepatitis virus were prepared and tested in Balb/c mice against the SARS-CoV challenge <xref rid="b0245" ref-type="bibr">[49]</xref>. The addition of alum adjuvant in the chimeric VLPs enhanced the induction of neutralizing antibodies and protected the mice from the SARS-CoV challenge. MERS-CoV and SARS-CoV&#8217;s full-length spike nanoparticles, in combination with adjuvants (Alum/Matrix M&#8482;), were able to produce high titers of neutralizing antibodies in mice <xref rid="b0250" ref-type="bibr">[50]</xref>. The RBD protein variants in deglycosylated form, to scale-up production of the RBD vaccine candidate, were expressed as recombinant proteins in yeast. The alum adjuvanted preparation induced significantly stronger RBD-specific antibody responses and a higher level of neutralizing antibodies against SARS-CoV <xref rid="b0255" ref-type="bibr">[51]</xref>. Similarly, alum adjuvanted MERS-CoV nanoparticles and recombinant MERS-CoV RBD protein vaccines could elicit neutralizing antibodies and protect the Rhesus macaques (<xref rid="t0015" ref-type="table">Table. 3</xref>
) <xref rid="b0260" ref-type="bibr">[52]</xref>, <xref rid="b0265" ref-type="bibr">[53]</xref>
<table-wrap position="float" id="t0015" orientation="portrait"><label>Table 3</label><caption><p>Important vaccine studies on MERS-CoV.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr. No.</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Vaccine candidate</th><th colspan="1" rowspan="1">Animal model</th><th colspan="1" rowspan="1">Results</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Alum&#160;+&#160;CpG</td><td colspan="1" rowspan="1">Inactivated whole MERS-CoV</td><td colspan="1" rowspan="1">Ad5-hDPP4 transduced mice</td><td colspan="1" rowspan="1">The adjuvant group showed increased protective immunity. The study did not observe enhanced pulmonary immunopathology</td><td colspan="1" rowspan="1"><xref rid="b0190" ref-type="bibr">[38]</xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Alum/MF59</td><td colspan="1" rowspan="1">Inactivated MERS-CoV vaccine</td><td colspan="1" rowspan="1">hCD26/DPP4 transgenic mice</td><td colspan="1" rowspan="1">Adjuvant groups showed increased antibody responses which were protective; however, the study observed hypersensitivity-type lung immunopathologic reaction on viral challenge</td><td colspan="1" rowspan="1"><xref rid="b0195" ref-type="bibr">[39]</xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">MERS-CoV VLPs</td><td colspan="1" rowspan="1">Rhesus macaques</td><td colspan="1" rowspan="1">Induced viral neutralizing antibodies, RBD specific IgG antibodies. Also elicited Th1 cell-mediated immunity</td><td colspan="1" rowspan="1"><xref rid="b0260" ref-type="bibr">[52]</xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">MERS-CoV RBD vaccine</td><td colspan="1" rowspan="1">Rhesus macaques</td><td colspan="1" rowspan="1">Robust induction of neutralizing antibodies. Vaccination decreased the viral load of lung, trachea, and oropharyngeal swabs of monkeys. Provided partial protection on viral challenge</td><td colspan="1" rowspan="1"><xref rid="b0265" ref-type="bibr">[53]</xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">MERS-CoV spike protein nanoparticles/ Ad5/MERS (S)</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Heterologous as well as spike nanoparticle homologous vaccination induced neutralizing antibodies and protected the animals on the viral challenge. The heterologous strategy could elicit both Th1 and Th2 responses.</td><td colspan="1" rowspan="1"><xref rid="b0740" ref-type="bibr">[148]</xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">Poly(I:C)/Alum</td><td colspan="1" rowspan="1">Chimeric VLPs expressing RBD of MERS-CoV</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Poly(I:C) group showed higher neutralizing antibodies than that of alum. RBD-specific humoral and cellular immune response. Antisera prevented pseudotyped MERS-CoV entry into susceptible cells</td><td colspan="1" rowspan="1"><xref rid="b0480" ref-type="bibr">[96]</xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">MF59</td><td colspan="1" rowspan="1">MERS-CoV Trimeric RBD vaccine</td><td colspan="1" rowspan="1">hDPP4 transduced mice</td><td colspan="1" rowspan="1">Induced robust RBD-specific neutralizing antibodiesProtected the animals from lethal viral challenge</td><td colspan="1" rowspan="1"><xref rid="b0320" ref-type="bibr">[64]</xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Alum/CpG</td><td colspan="1" rowspan="1">A recombinant N-terminal domain (rNTD) of MERS-CoV spike protein vaccine candidate</td><td colspan="1" rowspan="1">Ad5-hDPP4 transduced mice</td><td colspan="1" rowspan="1">Induced high titers of neutralizing antibodies. Inclusion of adjuvants (alum&#160;+&#160;CpG) caused activation of both Th1 and Th1 responses. The vaccine protected the animals on viral challenge</td><td colspan="1" rowspan="1"><xref rid="b0495" ref-type="bibr">[99]</xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">MF59</td><td colspan="1" rowspan="1">MERS-CoV RBD fused with human Fc</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Potent induction of viral neutralizing antibodies. Dose as low as 1&#160;&#956;g was sufficient to induce strong humoral and cellular immune responses</td><td colspan="1" rowspan="1"><xref rid="b0290" ref-type="bibr">[58]</xref>, <xref rid="b0745" ref-type="bibr">[149]</xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Montanide ISA51</td><td colspan="1" rowspan="1">MERS-CoV RBD</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Induced neutralizing antibodies. Neutralized MERS-CoV infection in cell culture</td><td colspan="1" rowspan="1"><xref rid="b0370" ref-type="bibr">[74]</xref></td></tr><tr><td colspan="1" rowspan="1">15</td><td colspan="1" rowspan="1">Matrix&#8482; M</td><td colspan="1" rowspan="1">MERS-CoV S nanoparticles vaccine</td><td colspan="1" rowspan="1">Mice</td><td colspan="1" rowspan="1">Vaccine elicited strong anti-S neutralizing antibodies and protected the mice from viral infection</td><td colspan="1" rowspan="1"><xref rid="b0750" ref-type="bibr">[150]</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="s0020"><label>2.2</label><title>MF59</title><p id="p0045">MF59 is an oil-in-water type immunogenic adjuvant which consists of squalene and two surfactants, Tween 80 and Span 85. The MF59 is a safe, well-tolerated, and potent adjuvant that has been used in pandemic (Focetria&#174; and Celtura&#174;) and seasonal influenza (Fluad&#174;) vaccines in many countries (<xref rid="t0005" ref-type="table">Table. 1</xref>) <xref rid="b0270" ref-type="bibr">[54]</xref>, <xref rid="b0275" ref-type="bibr">[55]</xref>. The inclusion of the MF59 adjuvant in the influenza vaccine has been reported to induce higher levels of antigen-specific antibody levels, higher HAI titers (hemagglutination inhibiting), and better protection <xref rid="b0280" ref-type="bibr">[56]</xref>, <xref rid="b0285" ref-type="bibr">[57]</xref>, <xref rid="b0290" ref-type="bibr">[58]</xref>. Though it favors Th2-type response like alum, MF59 activates more CD4 T cells and produces higher antibody tiers against the HA (hemagglutinin) of the influenza virus <xref rid="b0295" ref-type="bibr">[59]</xref>. The MF59 has been tested as an adjuvant with many other vaccines against bacteria and viruses, including SARS-CoV. Immunization with inactivated SARS-CoV vaccine adjuvanted with MF59 protected mice from challenge with the virus. The vaccine was able to elicit neutralizing antibodies after only 2 doses <xref rid="b0300" ref-type="bibr">[60]</xref>. Subunit vaccines based on S1 protein and RBD epitopes of MERS-CoV when co-administered with MF59, significantly augmented their immunogenicity resulting in strong induction of IgG and neutralizing antibody response. The preparations protected the mice from lethal virus challenge <xref rid="b0305" ref-type="bibr">[61]</xref>, <xref rid="b0310" ref-type="bibr">[62]</xref>, <xref rid="b0315" ref-type="bibr">[63]</xref>. Many MERS-CoV RBD candidate vaccines adjuvanted with MF59 were developed and tested in mice. These vaccines elicited neutralizing antibodies and protected the hDPP4 transduced mice from the lethal challenge (<xref rid="t0015" ref-type="table">Table. 3</xref>) <xref rid="b0315" ref-type="bibr">[63]</xref>, <xref rid="b0320" ref-type="bibr">[64]</xref>.</p></sec><sec id="s0025"><label>2.3</label><title>Montanide ISA-51</title><p id="p0050">Montanide is a water-in-oil (w/o) emulsion that contains mineral oil and surfactant from mannide monooleate family. It possesses immunostimulatory activity and works by the depot formation at the site of injection resulting in a slower release of antigens, local inflammation, and recruitment of antigen-presenting cells (APCs). It enhances antibody titer as well as cytotoxic T-lymphocyte (CTL) activity against the antigen it is formulated with <xref rid="b0325" ref-type="bibr">[65]</xref>, <xref rid="b0330" ref-type="bibr">[66]</xref>. It is well tolerated in humans as compared to FIA (Freund&#8217;s Incomplete Adjuvant) and has been tested in vaccines against AIDS (Acquired Immunodeficiency Syndrome), malaria, cancer, and influenza with varying degree of success <xref rid="b0335" ref-type="bibr">[67]</xref>, <xref rid="b0340" ref-type="bibr">[68]</xref>, <xref rid="b0345" ref-type="bibr">[69]</xref>, <xref rid="b0350" ref-type="bibr">[70]</xref>. The combination of Montanide ISA-51 and CpG ODN (oligodeoxynucleotide) has been used widely in many vaccines as the combination exerts a synergistic effect in boosting the Th1 immune response. Montanide ISA-51 and CpG were used to emulsify the recombinant N protein of SARS-CoV. The formulation elicited strong Th1 immune responses in mice and macaques <xref rid="b0355" ref-type="bibr">[71]</xref>. The synthetic peptides of the spike protein of SARS-CoV formulated with an adjuvant Montanide ISA-51/CpG combination, elicited strong antibody titer in immunized animals that were capable of inhibiting SARS-CoV pseudovirus entry into HepG2 cells <xref rid="b0360" ref-type="bibr">[72]</xref>. A DNA vaccine encoding SARS-CoV N protein elicited a potent N protein-specific immune response when co-administered with Montanide ISA-51/CpG adjuvants <xref rid="b0365" ref-type="bibr">[73]</xref>. The recombinant RBD of MERS-CoV when adjuvanted with Montanide ISA-51, induced high titers of serum antibodies that could neutralize the virus in cell culture <xref rid="b0370" ref-type="bibr">[74]</xref>. The above pieces of evidence from the previous studies indicate that Montanide ISA-51 may increase the immunogenicity of the vaccines based on recombinant spike protein or synthetic peptides corresponding to RBD of S protein. Further, it may be used along with CpG ODN to induce an overall Th1 biased immune response as a predominantly Th2 immune response seems to cause ADE on the viral challenge following immunization.</p></sec><sec id="s0030"><label>2.4</label><title>AS01<sub>B</sub> and AS03<sub>A</sub></title><p id="p0055">These are oil-in-water adjuvant systems developed by GlaxoSmithKline (GSK). The AS01 (adjuvant system 01) is a liposome-based adjuvant that is consist of monophosphoryl lipid A (MPL) and a saponin molecule (QS-21), whereas AS03 (adjuvant system 03) is an &#945;-tocopherol and squalene-based adjuvant that has been used in GSK's A/H1N1 pandemic flu vaccine Pandemrix&#174;. The MPL is extracted from <italic toggle="yes">Salmonella minnesota</italic> and QS-21 is purified from the bark of the South American tree <italic toggle="yes">Quillaja saponaria</italic> Molina. The MPL signals through Toll-like receptor-4 (TLR4), which results in the activation of APCs and the production of cytokines and interferons (IFNs). Q-21 is reported to induce antigen-specific antibody response as well as cell-mediated immunity <xref rid="b0375" ref-type="bibr">[75]</xref>, <xref rid="b0380" ref-type="bibr">[76]</xref>. When co-administered with recombinant SARS-CoV S protein, Q-21 induced high titers of antigen-specific serum antibodies and protected from viral infection <xref rid="b0385" ref-type="bibr">[77]</xref>. The AS01 system has been used in recently developed RTS,S/AS01 malaria vaccine as well as tested in Herpes zoster subunit vaccine, polyprotein HIV-1 vaccine and tuberculosis (Mtb72F/AS02 candidate) vaccine <xref rid="b0390" ref-type="bibr">[78]</xref>, <xref rid="b0395" ref-type="bibr">[79]</xref>, <xref rid="b0400" ref-type="bibr">[80]</xref>, <xref rid="b0405" ref-type="bibr">[81]</xref>. Further, these adjuvants have also been used with inactivated SARS-CoV vaccine preparation in mice and hamsters. The AS01<sub>B</sub>-adjuvanted vaccine was slightly more immunogenic than the AS03<sub>A</sub>-adjuvanted vaccine. The vaccine in animals immunized with adjuvant provided better protection than the non-adjuvanted vaccine. Importantly, the study did not observe enhance disease (ADE) in the lungs or liver of hamsters following SARS-CoV challenge <xref rid="b0410" ref-type="bibr">[82]</xref>.</p></sec><sec id="s0035"><label>2.5</label><title>Delta inulin (Advax&#8482;)</title><p id="p0060">Delta inulin (DI) is one of the many isoforms of inulin polysaccharide, which is stable at a higher temperature and has better immune potency. It activates the complement system and, when co-administered with antigen, helps mount a robust antigen-specific adaptive immune response consisting of both antibody and cell-mediated immunity (a Th0 adjuvant property) <xref rid="b0415" ref-type="bibr">[83]</xref>, <xref rid="b0420" ref-type="bibr">[84]</xref>, <xref rid="b0425" ref-type="bibr">[85]</xref>. A balanced enhancement of both Th1 and Th2 responses was observed when DI (Advax&#8482;) adjuvant was co-administered with an inactivated JEV (Japanese Encephalitis Virus) and influenza vaccines, which conferred the protection against the viral challenges <xref rid="b0415" ref-type="bibr">[83]</xref>, <xref rid="b0430" ref-type="bibr">[86]</xref>. Similarly, when recombinant spike protein or inactivated SARS-CoV vaccine was co-administered with delta inulin plus CpG oligonucleotide as adjuvants, the combination significantly enhanced serum neutralizing antibody titers without causing lung immunopathology, which was not the case when alum was used instead of delta inulin <xref rid="b0225" ref-type="bibr">[45]</xref>.</p></sec><sec id="s0040"><label>2.6</label><title>TLR agonist adjuvants</title><p id="p0065">TLRs are pattern recognition receptors (PRRs) that identify pathogen-associated molecular patterns (PAMPs). These are present on cell surfaces as well as in endosomal compartments. Interaction with the appropriate ligand triggers the release of proinflammatory cytokines and type &#8722;1 IFNs (Interferons), which activates the cells of the innate and adaptive immune system leading to antigen-specific enhanced humoral and cell-mediated responses <xref rid="b0435" ref-type="bibr">[87]</xref>. Therefore, TLR ligands have been widely studied and tested as immune adjuvants in many human and veterinary vaccine preparations against infectious diseases <xref rid="b0440" ref-type="bibr">[88]</xref>, <xref rid="b0445" ref-type="bibr">[89]</xref>, <xref rid="b0450" ref-type="bibr">[90]</xref>. Different TLR ligands induce a different type of immune response (Th1/Th2/Th0) depending on the signaling pathway involved. The TLRs that have been widely used in vaccine adjuvant studies and their ligands are as follow: TLR3 (dsRNA), 4 (LPS), 5 (Flagellin), 7 (ssRNA), 8(ssRNA) and 9 (unmethylated CpG oligonucleotide) <xref rid="b0440" ref-type="bibr">[88]</xref>. Out of these, only TLR4 ligand which is MPL has been approved for use in human vaccine formulations such as Human papillomavirus vaccine (Cervarix&#8482;), hepatitis (Fendrix&#174;, GSK Biologicals) and malaria (RTS, S/AS01 or Mosquirix). Nevertheless, many other TLR adjuvants have shown promising results and may make their way to human vaccine formulation in time to come.</p><p id="p0070">TLR ligands have been tested with the inactivated SARS-CoV vaccines since an inactivated vaccine with alum adjuvant has been reported to cause eosinophil infiltration in the lungs of immunized animals following live viral challenge. The TLR ligands [lipopolysaccharide, poly(U), and poly(I:C)], and the vaccine combination protected the animals with significantly reduced eosinophil infiltration in the lungs <xref rid="b0455" ref-type="bibr">[91]</xref>. Intranasal administration of a TLR3 agonist, poly(I:C), induced IFN-&#946; and IFN-&#947; production and protected the animals from SARS-CoV infection. Therefore, the poly(I:C) as a prophylactic measure should be further evaluated for use in aged or high-risk individuals <xref rid="b0460" ref-type="bibr">[92]</xref>. There are many ways an intranasal application of vaccines may benefit. The mucosal immune response generated following intranasal vaccine application, may block the viral entry, and alleviate the concern associated with systemic administration of inactivated vaccine i.e. immunopathology in the lungs. Mice immunized with inactivated SARS-CoV and CpG resulted in the local production of specific IgA and neutralizing antibodies in serum. This strategy may offer double protection; once at the site of entry and the second when the virus enters the circulation <xref rid="b0440" ref-type="bibr">[88]</xref>. Similar results were observed by another lab that reported induction of significant levels of SARS-CoV specific IgG antibodies in sera, and a detectable amount of IgA antibodies in sera and mucosal secretions when an inactivated vaccine adjuvanted with CpG ODN 2006 was administered intranasally <xref rid="b0470" ref-type="bibr">[94]</xref>. A TLR3 ligand, PIKA (Polyinosinic-Polycytidylic Acid Based Adjuvant) which a stabilized derivative of poly(I:C), also produced similar results when administered with inactivated SARS-CoV vaccine. Both, the intranasal and intraperitoneal, administration of PIKA with inactivated SARS-CoV induced significant levels of both mucosal and serum antibodies <xref rid="b0475" ref-type="bibr">[95]</xref>. Moreover, poly(I:C) was superior to alum with a Chimeric VLPs expressing MERS-CoV RBD protein vaccine when administered to mice. Poly(I:C) elicited stronger neutralizing antibody as well as cell-mediated responses that prevented pseudotyped virus entry into susceptible cells <xref rid="b0480" ref-type="bibr">[96]</xref>.</p><p id="p0075">The CpG ODN, poly(I:C), and R848(TLR7/8) ligands when used with HLA-A*0201 restricted SARS-CoV S epitopes, all three agonists enhanced the epitope-specific CD8<sup>+</sup> T cells, though the effect was more pronounced with CpG ODN. The immune response induced was stated to carry a memory cell phenotype that had long-term survival ability <xref rid="b0485" ref-type="bibr">[97]</xref>. Further, there are concerns the spike protein subunit vaccine adjuvanted only with alum (favors Th2 response) might trigger immunopathology in the lungs, therefore; inclusion of a TLR ligand that favors Th1 response may provide dual benefits, reduction in ADE as well as the activation of both the arms of the immune system. Further, a combination of either a recombinant S protein of SARS-CoV or an N-terminal domain (rNTD) of MERS-CoV with alum and CpG, induced high IgG2a antibody titers and IFN-&#947; production <xref rid="b0490" ref-type="bibr">[98]</xref>, <xref rid="b0495" ref-type="bibr">[99]</xref>.</p></sec><sec id="s0045"><label>2.7</label><title>Recombinant Onchocerca volvulus activation associated protein-1 (rOv-ASP-1)</title><p id="p0080">Many helminth-derived molecules have been shown to have potent immunostimulatory effects, including ASP-1. The ASP-1 is present in helminth <italic toggle="yes">Onchocerca volvulus.</italic> A recombinant ASP-1 (r<italic toggle="yes">Ov</italic>-ASP-1) is reported to induce a mix of Th1 and Th2 responses when included with vaccine antigen; however, depending on the antigen, it could also activate a predominantly Th1 type of immune response <xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0505" ref-type="bibr">[101]</xref>. Therefore, it can be beneficial in a condition where bits of help from both the arms of the immune response is needed to clear the infection. Further, the immune response induced against the ASP-1 protein adjuvant did not affect its adjuvant activity on subsequent boost <xref rid="b0510" ref-type="bibr">[102]</xref>. ASP-1 has been shown to improve IgG1 and IgG2a antibody levels against commercially available vaccines such as influenza and rabies, and the adjuvant effect observed was higher than either traditional adjuvant alum, or MPL plus trehalose dicorynomycolate (TDM) <xref rid="b0500" ref-type="bibr">[100]</xref>, <xref rid="b0515" ref-type="bibr">[103]</xref>, <xref rid="b0520" ref-type="bibr">[104]</xref>. A recombinant ASP-1 protein when included with recombinant SARS-CoV spike protein antigen or an RBD containing vaccine, the combinations induced a mixed immune response with Th1 dominance <xref rid="b0500" ref-type="bibr">[100]</xref>. Similar findings were observed when r<italic toggle="yes">Ov</italic>-ASP-1 was used as an adjuvant with either S protein of SARS-CoV or HIV-1gp120 <xref rid="b0525" ref-type="bibr">[105]</xref>. Further, immunization with RBD of SARS-CoV plus r<italic toggle="yes">Ov</italic>-ASP-1 in NHPs resulted in a high titer of neutralizing anti-RBD antibodies with only low levels of anti- r<italic toggle="yes">Ov</italic>-ASP-1 antibodies <xref rid="b0510" ref-type="bibr">[102]</xref>.</p></sec><sec id="s0050"><label>2.8</label><title>Protollin</title><p id="p0085">A complex of Proteosomes with LPS derived from <italic toggle="yes">Shigella flexneri</italic> is named as Protollin, whereas Proteosomes itself contain hydrophobic outer membrane proteins derived from <italic toggle="yes">Neisseria meningitides.</italic> Protollin exerts its immunostimulatory effect via TLR2 and TLR4 signaling resulting in the production of cytokines, IFNs, and the activation of APCs. Intranasal administration of Protollin with influenza antigen (split or recombinant HA) induced both serum IgG and mucosal secretory IgA that protected the mice from lethal virus challenge <xref rid="b0530" ref-type="bibr">[106]</xref>, <xref rid="b0535" ref-type="bibr">[107]</xref>. Further, its application was shown to be effective in reducing allergic asthma in a mouse model <xref rid="b0540" ref-type="bibr">[108]</xref>, protective against the development of pneumonia in a murine model of Shigella infection <xref rid="b0545" ref-type="bibr">[109]</xref> and safe and well-tolerated in healthy adults <xref rid="b0550" ref-type="bibr">[110]</xref>. Protollin was an effective, safe, and immunogenic and induced protective antibody response consisting of both serum IgG and mucosal IgA in humans when administered intranasally with trivalent influenza vaccine <xref rid="b0555" ref-type="bibr">[111]</xref>. Protollin when administered intranasally with recombinant SARS-CoV S protein, induced significant levels of antigen-specific serum IgG and mucosal IgA antibodies as compared alum plus recombinant S protein administered via intramuscular route, and protected the mice from the live viral challenge <xref rid="b0560" ref-type="bibr">[112]</xref>. Therefore, as evidence reflects, Protollin adjuvant appears to be safe and well-tolerated in human, more importantly, its ability to induce both serum and mucosal immunity might prove to be beneficial and should be explored further in SARS-CoV-2 vaccine development.</p></sec></sec><sec id="s0055"><label>3</label><title>Antibody-dependent enhancement of disease (ADE)</title><p id="p0090">Many investigations have revealed an over activation of the immune system when an animal is challenged with the live virus following immunization. It causes immunopathological changes because of the excessive release of pro-inflammatory cytokines (cytokine storm) such as IL-2, IL-7, IL-8, IL-9, IL-10, IL-17, IL-1&#946;, G-CSF, GM-CSF, and TNF&#945;. <xref rid="b0765" ref-type="bibr">[153]</xref>, <xref rid="b0770" ref-type="bibr">[154]</xref>, <xref rid="b0775" ref-type="bibr">[155]</xref>. ADE or immune enhancement occurs when a virus gains access into the immune cells while adhered to the antibodies, leading to an increase in infectivity and virulence of the virus. Once inside the cells, which aren&#8217;t the usual target, the virus multiplies and releases its progenies infecting more cells <xref rid="b0780" ref-type="bibr">[156]</xref>. Many viruses such as dengue, yellow fever, HIV, and CoVs have been reported to induce ADE <xref rid="b0785" ref-type="bibr">[157]</xref>. Most pieces of evidence suggest viruses exploit the Fc receptor (FcR) on the immune cells to gain entry while being attached to the antibody-binding site of the antibodies. The Fc region of the antibody has a sequence that binds to complement system or immune cells expressing FcR receptors <xref rid="b0790" ref-type="bibr">[158]</xref>, <xref rid="b0795" ref-type="bibr">[159]</xref>. The presence of high levels of non-neutralizing antibodies appears to be the primary reason that triggers ADE <xref rid="b0215" ref-type="bibr">[43]</xref>. Other factors that contribute include low-affinity or sub-optimal levels of neutralizing antibodies and isotype of antibodies induced [42,43]. The presence of circulating antibodies against related epitopes from different strains or related viruses may also contribute to the enhancement of disease <xref rid="b0800" ref-type="bibr">[160]</xref>. Though data is conflicting, it has been observed in many inactivated virus vaccine experiments on SARS and MERS-CoVs <xref rid="b0180" ref-type="bibr">[36]</xref>, <xref rid="b0195" ref-type="bibr">[39]</xref>, <xref rid="b0200" ref-type="bibr">[40]</xref>, <xref rid="b0205" ref-type="bibr">[41]</xref>. However, incorporation of a predominantly Th1 inducing adjuvant seemed to address the issue <xref rid="b0225" ref-type="bibr">[45]</xref>. There is no evidence yet that antibody-dependent disease enhancement could be associated with the SARS-CoV-2 vaccine, rather recent experiments with SARS-CoV-2 vaccines have shown promising results without ADE in rodents and macaques <xref rid="b0565" ref-type="bibr">[113]</xref>, <xref rid="b0575" ref-type="bibr">[115]</xref>, <xref rid="b0805" ref-type="bibr">[161]</xref>.</p></sec><sec id="s0060"><label>4</label><title>Ongoing developments</title><p id="p0095">Recent data available on vaccine studies with SARS-CoV-2 in NHPs appears promising. An inactivated vaccine (PiCoVacc) adjuvanted with alum, elicited spike, and RBD protein-specific neutralizing antibodies and protected the macaques on the viral challenge. Importantly, the study did not observe ADE in immunized animals (<xref rid="t0020" ref-type="table">Table. 4</xref>
) <xref rid="b0565" ref-type="bibr">[113]</xref>. The recombinant S1 protein of the virus fused with Fc and adjuvanted with saponin microemulsion, when administered to macaques, induced a strong anti-S1 neutralizing antibodies <xref rid="b0570" ref-type="bibr">[114]</xref>. The Oxford University&#8217;s vaccine candidate, ChAdOx1 nCoV-19 encoding the S protein of SARS-CoV-2, protected rhesus monkeys from developing pneumonia. The vaccine significantly reduced the viral loads in bronchoalveolar lavage fluid and respiratory tract tissue without causing disease enhancement in vaccinated monkeys <xref rid="b0805" ref-type="bibr">[161]</xref>. Further, a recently concluded Phase I clinical trial with Ad5-nCoV (adenovirus Type 5 vector) expressing S protein vaccine reported promising findings. The vaccine has been found to be safe, well-tolerated and induced both humoral and cellular immunity <xref rid="b0820" ref-type="bibr">[164]</xref>. Encouraging results have also been received from a recently concluded Phase I clinical trial for the MERS-CoV vaccine [<xref rid="t0025" ref-type="table">Table. 5</xref>
]. An MVA-MERS-S (MVA: modified vaccinia virus Ankara) DNA vaccine was safe, well-tolerated, and produced both humoral and cell-mediated immune responses in 87% of the participants after the second dose <xref rid="b0720" ref-type="bibr">[144]</xref>. The MVA vector technology may be repurposed to develop a COVID-19 vaccine by incorporating SARS-CoV-2 S protein. Further, to expedite the development of the SARS-CoV-2 vaccine, many leading vaccine manufacturers are coming together and collaborating. This has enabled them to share each other&#8217;s proprietary molecular compounds which already have some degree of safety approval. To date, 10 vaccine candidates have entered either phase I or II of clinical trials (<xref rid="t0030" ref-type="table">Table. 6</xref>
), and many are in preclinical or developing stages (<xref rid="t0035" ref-type="table">Table. 7</xref>
). Out of these, Ad5-nCoV (CanSino Biologics, Inc) is advancing quickly and has reached the second phase of clinical trials. Many of these are using the established adjuvant system with their COVID-19 vaccine candidates. An adjuvant based on TLR9 agonists (CpG 1018), which has been developed by Dynavax Technologies Corp., USA, is being used in a recombinant spike protein (S-Trimer) vaccine candidate against COVID-19 announced by Clover Biopharmaceutics, China <xref rid="b0580" ref-type="bibr">[116]</xref>. The CpG 1018 adjuvant has been used in an FDA (Food and Drug Administration) -approved hepatitis B vaccine (HEPLISAV-B&#174;). GlaxoSmithKline has also teamed up with many firms such as Xiamen Innovax Biotech and Sanofi, to make its adjuvant technology available to the collaborators for their vaccine candidates <xref rid="b0585" ref-type="bibr">[117]</xref>. Both Sanofi and Xiamen Innovax Biotech are using GSK&#8217;s AS03 adjuvant (squalene-based) in their recombinant protein vaccine candidates. Similarly, CSL (Commonwealth Serum Laboratories, Australia) and Seqirus, Germany have tied up to use the MF59 adjuvant, which employs novel molecular-clam technology, in their COVID-19 vaccine candidate <xref rid="b0590" ref-type="bibr">[118]</xref>. Novavax, (USA), on the other hand, is using its proprietary Matrix-M&#8482;&#160;adjuvant for a vaccine candidate (NVX-CoV2373), consisting of nanoparticles carrying SARS-CoV-2 spike protein antigens <xref rid="b0595" ref-type="bibr">[119]</xref>. Another Biopharma company, Soligenix, Inc., has collaborated with BTG Speciality Pharmaceutics. Soligenix will use a novel vaccine adjuvant (CoVaccine HT) from BTG, with its COVID-19 vaccine candidate <xref rid="b0600" ref-type="bibr">[120]</xref>. CoVaccine HT is an oil-in-water emulsion consisting of sucrose fatty acid sulfate easter (SFASE) and squalene, which has been reported to induce both humoral as well as cell-mediated immunity <xref rid="b0605" ref-type="bibr">[121]</xref>, <xref rid="b0610" ref-type="bibr">[122]</xref>. iBio has signed up an agreement with Infectious Disease Research Institute (IDRI, Seattle, US) in an effort to utilize their novel adjuvants such as GLA (Glucopyranosyl Lipid Adjuvant), a synthetic analogue of the MPL, for its SARS-CoV-2 VLP vaccine development <xref rid="b0615" ref-type="bibr">[123]</xref>, <xref rid="b0620" ref-type="bibr">[124]</xref>.<table-wrap position="float" id="t0020" orientation="portrait"><label>Table 4</label><caption><p>Recent studies on SARS-CoV-2 vaccine candidates.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr. No.</th><th colspan="1" rowspan="1">Vaccine candidate</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Animal model</th><th colspan="1" rowspan="1">Outcomes</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Inactivated SARS-CoV-2 virus vaccine candidate (PiCoVacc)</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">Rhesus macaques</td><td colspan="1" rowspan="1">The vaccine induced spike and RBD protein-specific neutralizing antibodies. Immunized macaques were protected from the lethal viral challenge. No ADE was observed</td><td colspan="1" rowspan="1"><xref rid="b0565" ref-type="bibr">[113]</xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">SARS-CoV-2 S1-Fc vaccine candidate</td><td colspan="1" rowspan="1">Saponin-based microemulsion</td><td colspan="1" rowspan="1">Cynomolgus monkeys</td><td colspan="1" rowspan="1">The monkeys developed high titers of S1-specific neutralizing antibodies</td><td colspan="1" rowspan="1"><xref rid="b0570" ref-type="bibr">[114]</xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">SARS-CoV-2 RBD vaccine candidate</td><td colspan="1" rowspan="1">MPLA and QuilA</td><td colspan="1" rowspan="1">Rodents</td><td colspan="1" rowspan="1">Vaccine elicited potent neutralizing antibodies. ADE was not observed.</td><td colspan="1" rowspan="1"><xref rid="b0575" ref-type="bibr">[115]</xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">ChAdOx1 nCoV-19</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Rhesus macaques</td><td colspan="1" rowspan="1">A single of ChAdOx1 nCoV-19 induced both humoral and cellular immune responses. The vaccine significantly reduced viral load in bronchoalveolar lavage fluid and respiratory tract tissue. The study observed no pneumonia and immune-enhanced disease in vaccinated rhesus macaques following viral challenge</td><td colspan="1" rowspan="1"><xref rid="b0805" ref-type="bibr">[161]</xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">DNA vaccine encoding S protein(INO-4800)</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Mice/Guinea pigs</td><td colspan="1" rowspan="1">The vaccine induced T-cell and neutralizing antibody responses. The antibodies blocked virus entry in vitro</td><td colspan="1" rowspan="1"><xref rid="b0810" ref-type="bibr">[162]</xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">DNA vaccine encoding S protein</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Rhesus macaques</td><td colspan="1" rowspan="1">The vaccinated animals developed humoral and T-cell responses. The neutralizing antibodies titers were comparable to convalescent humans and macaques. The vaccine reduced the viral loads and protected the animals on challenge.</td><td colspan="1" rowspan="1"><xref rid="b0815" ref-type="bibr">[163]</xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">Ad5-nCoV expressing S protein</td><td colspan="1" rowspan="1">&#8211;</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">The vaccine found to be safe, well-tolerated and immunogenic at 28&#160;days post-vaccination.Antibody responses peaked at day 28 post-vaccination and specific T-cell responses from day 14 post-vaccination.</td><td colspan="1" rowspan="1"><xref rid="b0820" ref-type="bibr">[164]</xref></td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0025" orientation="portrait"><label>Table 5</label><caption><p>SARS and MERS-CoV vaccine candidates that entered clinical trials.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr. No.</th><th colspan="1" rowspan="1">Vaccine</th><th colspan="1" rowspan="1">Type</th><th colspan="1" rowspan="1">Target</th><th colspan="1" rowspan="1">Developer</th><th colspan="1" rowspan="1">Status</th><th colspan="1" rowspan="1">Outcomes</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">DNA plasmid encoding S protein</td><td colspan="1" rowspan="1">DNA vaccine</td><td colspan="1" rowspan="1">MERS-CoV</td><td colspan="1" rowspan="1">Inovio pharmaceuticals</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">The study did not observe vaccine-induced serious adverse events. Mild systemic reactions occurred such as headache, myalgia, and fatigue. The dose-independent immune responses were detected in more than 85% of participants after two vaccinations. The vaccine induced both humoral and cell-mediated responses.</td><td colspan="1" rowspan="1"><xref rid="b0715" ref-type="bibr">[143]</xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">MVA-MERS-S</td><td colspan="1" rowspan="1">Non-replicating viral vector</td><td colspan="1" rowspan="1">MERS-CoV</td><td colspan="1" rowspan="1">IDT Biologika GmbH</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">No serious events were recorded. Mild swelling, induration, fatigue, headache, and malaise were observed in some participants.Both the humoral and cell-mediated immune responses were induced following homologous prime-boost immunization.</td><td colspan="1" rowspan="1"><xref rid="b0720" ref-type="bibr">[144]</xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">ChAdOx1 MERS</td><td colspan="1" rowspan="1">Non-replicating viral vector</td><td colspan="1" rowspan="1">MERS-CoV</td><td colspan="1" rowspan="1">University of Oxford</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">The vaccination induced mild adverse events that were self-limiting. No serious reactions or events were recorded. A single dose could elicit both humoral as well as cell-mediated immunity</td><td colspan="1" rowspan="1"><xref rid="b0725" ref-type="bibr">[145]</xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">DNA vaccine encoding S protein</td><td colspan="1" rowspan="1">DNA vaccine</td><td colspan="1" rowspan="1">SARS-CoV</td><td colspan="1" rowspan="1">National Institute of Allergy and Infectious Diseases (NIAID)</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">The vaccine was safe and well-tolerated. It induced neutralizing antibodies in all the participants and a CTL response in about 20% of participants.</td><td colspan="1" rowspan="1"><xref rid="b0730" ref-type="bibr">[146]</xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">Inactivated vaccine</td><td colspan="1" rowspan="1">Inactivated vaccine SARS-CoV vaccine (ISCV)</td><td colspan="1" rowspan="1">SARS-CoV</td><td colspan="1" rowspan="1">Sinovac Biotech Ltd, China</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1">The vaccine was safe and well-tolerated, some symptoms such as diarrhea and an increase in serum ALT were observed in some participants which were transient. The vaccine produced neutralizing antibodies against SARS-CoV.</td><td colspan="1" rowspan="1"><xref rid="b0735" ref-type="bibr">[147]</xref></td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0030" orientation="portrait"><label>Table 6</label><caption><p>SARS-CoV-2 vaccine candidates in clinical trials*.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr No</th><th colspan="1" rowspan="1">Vaccine candidates</th><th colspan="1" rowspan="1">Type</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Developer</th><th colspan="1" rowspan="1">Status</th><th colspan="1" rowspan="1">Reference</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">ChAdOx1 nCoV-19</td><td colspan="1" rowspan="1">Viral vector encoding SARS-CoV-2 spike protein</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">University of Oxford, Uk</td><td colspan="1" rowspan="1">Phase II/III</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04400838">NCT04400838</ext-link></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Encapsulated mRNA-1273</td><td colspan="1" rowspan="1">Spike protein</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Moderna, Inc., USA</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Phase I: NCT04283461Phase II: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04405076">NCT04405076</ext-link></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Inactivated SARS-CoV-2 vaccine</td><td colspan="1" rowspan="1">Inactivated virus vaccine</td><td colspan="1" rowspan="1">Alum</td><td colspan="1" rowspan="1">Sinovac Research and Development Co., Ltd., China</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">Phase I/II <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04383574">NCT04383574</ext-link> <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04352608">NCT04352608</ext-link></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">SARS-CoV-2 rS</td><td colspan="1" rowspan="1">Recombinant Spike Protein Nanoparticle vaccine</td><td colspan="1" rowspan="1">Matrix-M&#8482;</td><td colspan="1" rowspan="1">Novavax</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368988">NCT04368988</ext-link></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">BNT162a1/b1/b2/c2</td><td colspan="1" rowspan="1">RNA vaccines</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Biontech SE</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">Ad5-nCoV</td><td colspan="1" rowspan="1">Viral vector encoding spike protein</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">CanSino Biologics Inc./ Insitute of Biotechnology, Academy of Military Medical Sciences, PLA of China</td><td colspan="1" rowspan="1">Phase II</td><td colspan="1" rowspan="1">NCT04341389ChiCTR2000031781</td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">bacTRL-Spike</td><td colspan="1" rowspan="1">Engineered <italic toggle="yes">Bifidobacterium longum</italic> encoding SARS-CoV-2 S</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Symvivo Corporation</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04334980">NCT04334980</ext-link></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Inactivated SARS-CoV-2</td><td colspan="1" rowspan="1">Inactivated virus vaccine</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Wuhan Institute of Biological Products/Sinopharm</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">ChiCTR2000031809</td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">Inactivated SARS-CoV-2</td><td colspan="1" rowspan="1">Inactivated virus vaccine</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Beijing Institute of Biological Products/Sinopharm</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1">ChiCTR2000032459</td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">DNA plasmid vaccine with electroporation (INO-4800)</td><td colspan="1" rowspan="1">DNA vaccine</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Inovio Pharmaceuticals</td><td colspan="1" rowspan="1">Phase I</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04336410">NCT04336410</ext-link></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Inactivated SARS-CoV-2 vaccine</td><td colspan="1" rowspan="1">Inactivated vaccine</td><td colspan="1" rowspan="1">No</td><td colspan="1" rowspan="1">Chinese Academy of Medical Sciences</td><td colspan="1" rowspan="1">Phase I/II</td><td colspan="1" rowspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04412538">NCT04412538</ext-link></td></tr></tbody></table><table-wrap-foot><fn><p>*As on 30/05/2020.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="t0035" orientation="portrait"><label>Table 7</label><caption><p>SARS-CoV-2 adjuvanted vaccine candidates in pre-clinical/developing stages.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Sr. No.</th><th colspan="1" rowspan="1">Vaccine candidates in developing/pre-clinical stage</th><th colspan="1" rowspan="1">Adjuvant</th><th colspan="1" rowspan="1">Developer(s)</th><th colspan="1" rowspan="1">References</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">Recombinant spike protein (S-Trimer)</td><td colspan="1" rowspan="1">CpG 1018</td><td colspan="1" rowspan="1">Clover Biopharmaceutics, China &amp; Dynavax Technologies Corp., USA</td><td colspan="1" rowspan="1"><xref rid="b0580" ref-type="bibr">[116]</xref></td></tr><tr><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">Recombinant protein vaccine</td><td colspan="1" rowspan="1">AS03</td><td colspan="1" rowspan="1">Xiamen Innovax Biotech &amp; GlaxoSmithKline</td><td colspan="1" rowspan="1"><xref rid="b0585" ref-type="bibr">[117]</xref></td></tr><tr><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">Recombinant protein vaccine</td><td colspan="1" rowspan="1">AS03</td><td colspan="1" rowspan="1">Sanofi &amp; GlaxoSmithKline</td><td colspan="1" rowspan="1"><xref rid="b0585" ref-type="bibr">[117]</xref></td></tr><tr><td colspan="1" rowspan="1">4</td><td colspan="1" rowspan="1">Recombinant protein vaccine</td><td colspan="1" rowspan="1">MF59 adjuvant</td><td colspan="1" rowspan="1">Commonwealth Serum Laboratories, Australia &amp; Seqirus, Germany</td><td colspan="1" rowspan="1"><xref rid="b0590" ref-type="bibr">[118]</xref></td></tr><tr><td colspan="1" rowspan="1">5</td><td colspan="1" rowspan="1">SARS-CoV-2 spike protein nanoparticles</td><td colspan="1" rowspan="1">Matrix-M&#8482;</td><td colspan="1" rowspan="1">Novavax, (USA)</td><td colspan="1" rowspan="1"><xref rid="b0595" ref-type="bibr">[119]</xref></td></tr><tr><td colspan="1" rowspan="1">6</td><td colspan="1" rowspan="1">Vaccine candidate</td><td colspan="1" rowspan="1">CoVaccine HT</td><td colspan="1" rowspan="1">Soligenix, Inc., &amp; BTG Speciality Pharmaceutics</td><td colspan="1" rowspan="1"><xref rid="b0600" ref-type="bibr">[120]</xref></td></tr><tr><td colspan="1" rowspan="1">7</td><td colspan="1" rowspan="1">SARS-CoV-2 VLP vaccine</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">iBIO &amp; Infectious Disease Research Institute (IDRI, Seattle, US)</td><td colspan="1" rowspan="1"><xref rid="b0615" ref-type="bibr">[123]</xref></td></tr><tr><td colspan="1" rowspan="1">8</td><td colspan="1" rowspan="1">Inactivated virus vaccine</td><td colspan="1" rowspan="1">CpG 1018</td><td colspan="1" rowspan="1">Sinovac/Dynavax</td><td colspan="1" rowspan="1"><xref rid="b0755" ref-type="bibr">[151]</xref></td></tr><tr><td colspan="1" rowspan="1">9</td><td colspan="1" rowspan="1">Inactivated virus vaccine</td><td colspan="1" rowspan="1">CpG 1018</td><td colspan="1" rowspan="1">Valneva/Dynavax</td><td colspan="1" rowspan="1"><xref rid="b0755" ref-type="bibr">[151]</xref></td></tr><tr><td colspan="1" rowspan="1">10</td><td colspan="1" rowspan="1">SARS-CoV-2 protein subunit (RBD)</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Biological E Ltd</td><td colspan="1" rowspan="1"><xref rid="b0755" ref-type="bibr">[151]</xref></td></tr><tr><td colspan="1" rowspan="1">11</td><td colspan="1" rowspan="1">Recombinant spike protein</td><td colspan="1" rowspan="1">Advax&#8482; (delta inulin)</td><td colspan="1" rowspan="1">Vaxine Pty Ltd</td><td colspan="1" rowspan="1"><xref rid="b0755" ref-type="bibr">[151]</xref></td></tr></tbody></table></table-wrap></p></sec><sec id="s0065"><label>5</label><title>Conclusions</title><p id="p0100">The experience and knowledge generated from the past vaccine studies with different adjuvants against similar CoVs may expedite the development of an adjuvanted vaccine against COVID-19. The inclusion of an adjuvant may cut down the amount of antigen significantly in a vaccine, especially when vaccine candidates are recombinant spike/RBD protein. This could help address an overwhelming demand for the vaccine in a pandemic in a short time. So far, there is no firm evidence whether an antibody response is sufficient or a T-cell response is also critical for recovery from SARS-CoV-2 infection. Past studies on similar CoVs have observed that T-cell immunity also plays a crucial role in clearing the viral infection. Therefore, the inclusion of an adjuvant with a recombinant spike/RBD protein vaccine candidate, which stimulates a mixed immune response, such as delta inulin, CoVaccine HT, Matrix-M&#8482;, MF59&#174;, AS03, and rOv-ASP-1, might be appropriate in such a scenario. However, selecting an adjuvant that has a proven safety profile and efficacy may be beneficial for obtaining quick clearance from the regulatory bodies. Though delta inulin, CoVaccine HT, Matrix-M&#8482;, and rOv-ASP-1 have shown good safety and efficacy in pre-clinical and clinical trials, CpG 1018, MF59&#174; and AS03 are already approved for human vaccines and their inclusion may expedite the vaccine development process. Further, Protollin has shown promising results in pre-clinical studies in inducing both systemic and mucosal immune responses against viruses affecting the respiratory system and should be further evaluated with SARS-CoV-2. A few past studies with inactivated SARS-CoV and MERS-CoV vaccines alone or with adjuvant have been reported to cause antibody-mediated enhancement of disease on the live viral challenge following immunization, however, so far, we have no conclusive evidence that the same phenomenon will happen with SARS-CoV-2. In fact, a recent study on rhesus macaque with alum adjuvanted inactivated vaccine revealed the development of protective immune responses without causing disease enhancement <xref rid="b0565" ref-type="bibr">[113]</xref>. Nevertheless, other studies have suggested the use of a Th1 favoring adjuvant such as CpG 1018, might help ease such concerns.</p></sec><sec sec-type="COI-statement"><title>Conflict of interest</title><p id="p0105">None</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>R.</given-names></name><name name-style="western"><surname>Leung</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Lau</surname><given-names>E.H.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>X.</given-names></name></person-group><article-title>Early transmission dynamics in Wuhan, China, of novel coronavirus&#8211;infected pneumonia</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2001316</pub-id><pub-id pub-id-type="pmcid">PMC7121484</pub-id><pub-id pub-id-type="pmid">31995857</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Horby</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Hayden</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>The Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30185-9</pub-id><pub-id pub-id-type="pmcid">PMC7135038</pub-id><pub-id pub-id-type="pmid">31986257</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z.G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Z.W.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Pei</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>M.L.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2008-3</pub-id><pub-id pub-id-type="pmcid">PMC7094943</pub-id></element-citation></ref><ref id="b0020"><label>4</label><mixed-citation publication-type="other" id="h0020">World Health Organization, 2020. WHO Director-General&#8217;s remarks at the media briefing on 2019-nCoV on 11 February 2020.&#160;Internet] World Health Organization.</mixed-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.F.W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.K.W.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yip</surname><given-names>C.C.Y.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>R.W.S.</given-names></name><name name-style="western"><surname>Tsoi</surname><given-names>H.W.</given-names></name></person-group><article-title>A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster</article-title><source>The Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>514</fpage><lpage>523</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30154-9</pub-id><pub-id pub-id-type="pmcid">PMC7159286</pub-id><pub-id pub-id-type="pmid">31986261</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#8211;infected pneumonia in Wuhan, China</article-title><source>Jama</source><volume>323</volume><issue>11</issue><year>2020</year><fpage>1061</fpage><lpage>1069</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.1585</pub-id><pub-id pub-id-type="pmcid">PMC7042881</pub-id><pub-id pub-id-type="pmid">32031570</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>X.</given-names></name><name name-style="western"><surname>Ren</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Z.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>The Lancet</source><volume>395</volume><issue>10223</issue><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30183-5</pub-id><pub-id pub-id-type="pmcid">PMC7159299</pub-id><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Aiping</given-names></name><name name-style="western"><surname>Peng</surname><given-names>Yousong</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Baoying</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Xiao</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Xianyue</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Peihua</given-names></name><name name-style="western"><surname>Meng</surname><given-names>Jing</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Zhaozhong</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Zheng</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Jiangyuan</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Jie</given-names></name><name name-style="western"><surname>Quan</surname><given-names>Lijun</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Zanxian</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Wenjie</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Genhong</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Taijiao</given-names></name></person-group><article-title>Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China</article-title><source>Cell Host Microbe</source><volume>27</volume><issue>3</issue><year>2020</year><fpage>325</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2020.02.001</pub-id><pub-id pub-id-type="pmid">32035028</pub-id><pub-id pub-id-type="pmcid">PMC7154514</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Si</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>B.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.D.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><issue>7798</issue><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2012-7</pub-id><pub-id pub-id-type="pmcid">PMC7095418</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name name-style="western"><surname>Cui</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>17</volume><issue>3</issue><year>2019</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">30531947</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41579-018-0118-9</pub-id><pub-id pub-id-type="pmcid">PMC7097006</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>J.F.W.</given-names></name><name name-style="western"><surname>Kok</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>To</surname><given-names>K.K.W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan</article-title><source>Emerging Microbes Infect.</source><volume>9</volume><issue>1</issue><year>2020</year><fpage>221</fpage><lpage>236</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/22221751.2020.1719902</pub-id><pub-id pub-id-type="pmcid">PMC7067204</pub-id><pub-id pub-id-type="pmid">31987001</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="book" id="h0060"><person-group person-group-type="author"><name name-style="western"><surname>Fehr</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><chapter-title>Coronaviruses: an overview of their replication and pathogenesis</chapter-title><source>Coronaviruses</source><year>2015</year><publisher-name>Humana Press</publisher-name><publisher-loc>New York, NY</publisher-loc><fpage>1</fpage><lpage>23</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-2438-7_1</pub-id><pub-id pub-id-type="pmcid">PMC4369385</pub-id><pub-id pub-id-type="pmid">25720466</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bi</surname><given-names>Y.</given-names></name></person-group><article-title>Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</article-title><source>The Lancet</source><volume>395</volume><issue>10224</issue><year>2020</year><fpage>565</fpage><lpage>574</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)30251-8</pub-id><pub-id pub-id-type="pmcid">PMC7159086</pub-id><pub-id pub-id-type="pmid">32007145</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name></person-group><article-title>Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26</article-title><source>Nature</source><volume>500</volume><issue>7461</issue><year>2013</year><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">23831647</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature12328</pub-id><pub-id pub-id-type="pmcid">PMC7095341</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sauer</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bosch</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>DiMaio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors</article-title><source>Nat. Struct. Mol. Biol.</source><volume>26</volume><issue>12</issue><year>2019</year><fpage>1151</fpage><lpage>1157</lpage><pub-id pub-id-type="pmid">31792450</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41594-019-0334-7</pub-id><pub-id pub-id-type="pmcid">PMC7097669</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gui</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.</given-names></name></person-group><article-title>Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2</article-title><source>PLoS Pathog.</source><volume>14</volume><issue>8</issue><year>2018</year><object-id pub-id-type="publisher-id">e1007236</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1007236</pub-id><pub-id pub-id-type="pmcid">PMC6107290</pub-id><pub-id pub-id-type="pmid">30102747</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name></person-group><article-title>Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus</article-title><source>J. Virol.</source><volume>94</volume><issue>7</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00127-20</pub-id><pub-id pub-id-type="pmcid">PMC7081895</pub-id><pub-id pub-id-type="pmid">31996437</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name name-style="western"><surname>Coutard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Valle</surname><given-names>C.</given-names></name><name name-style="western"><surname>de Lamballerie</surname><given-names>X.</given-names></name><name name-style="western"><surname>Canard</surname><given-names>B.</given-names></name><name name-style="western"><surname>Seidah</surname><given-names>N.G.</given-names></name><name name-style="western"><surname>Decroly</surname><given-names>E.</given-names></name></person-group><article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade</article-title><source>Antiviral Res.</source><volume>176</volume><year>2020</year><object-id pub-id-type="publisher-id">104742</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2020.104742</pub-id><pub-id pub-id-type="pmcid">PMC7114094</pub-id><pub-id pub-id-type="pmid">32057769</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Park</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Tortorici</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wall</surname><given-names>A.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Veesler</surname><given-names>D.</given-names></name></person-group><article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title><source>Cell</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.02.058</pub-id><pub-id pub-id-type="pmcid">PMC7102599</pub-id><pub-id pub-id-type="pmid">32155444</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name name-style="western"><surname>Simmons</surname><given-names>G.</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Rennekamp</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Amberg</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Piefer</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bates</surname><given-names>P.</given-names></name></person-group><article-title>Characterization of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike glycoprotein-mediated viral entry</article-title><source>Proc. Natl. Acad. Sci.</source><volume>101</volume><issue>12</issue><year>2004</year><fpage>4240</fpage><lpage>4245</lpage><pub-id pub-id-type="pmid">15010527</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0306446101</pub-id><pub-id pub-id-type="pmcid">PMC384725</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name name-style="western"><surname>Millet</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Whittaker</surname><given-names>G.R.</given-names></name></person-group><article-title>Host cell proteases: Critical determinants of coronavirus tropism and pathogenesis</article-title><source>Virus Res.</source><volume>202</volume><year>2015</year><fpage>120</fpage><lpage>134</lpage><pub-id pub-id-type="pmid">25445340</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2014.11.021</pub-id><pub-id pub-id-type="pmcid">PMC4465284</pub-id></element-citation></ref><ref id="b0110"><label>22</label><mixed-citation publication-type="other" id="h0110"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/news-room/q-a-detail/q-a-coronaviruses+(12.00+PM%2c+01/04/2020)" id="ir005">https://www.who.int/news-room/q-a-detail/q-a-coronaviruses (12.00 PM, 01/04/2020)</ext-link>.</mixed-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Paddock</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Guarner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zaki</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Animal models and vaccines for SARS-CoV infection</article-title><source>Virus Res.</source><volume>133</volume><issue>1</issue><year>2008</year><fpage>20</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">17499378</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virusres.2007.03.025</pub-id><pub-id pub-id-type="pmcid">PMC2323511</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Vaccines for the prevention against the threat of MERS-CoV</article-title><source>Expert Rev. Vaccines</source><volume>15</volume><issue>9</issue><year>2016</year><fpage>1123</fpage><lpage>1134</lpage><pub-id pub-id-type="pmid">26985862</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2016.1167603</pub-id><pub-id pub-id-type="pmcid">PMC5097835</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name></person-group><article-title>SARS vaccine development</article-title><source>Emerg. Infect. Dis.</source><volume>11</volume><issue>7</issue><year>2005</year><fpage>1016</fpage><pub-id pub-id-type="pmid">16022774</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1107.050219</pub-id><pub-id pub-id-type="pmcid">PMC3371787</pub-id></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name name-style="western"><surname>Bonam</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Halmuthur</surname><given-names>S.K.M.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>S.</given-names></name></person-group><article-title>An overview of novel adjuvants designed for improving vaccine efficacy</article-title><source>Trends Pharmacol. Sci.</source><volume>38</volume><issue>9</issue><year>2017</year><fpage>771</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">28668223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2017.06.002</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name name-style="western"><surname>Aguilar</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>E.G.</given-names></name></person-group><article-title>Vaccine adjuvants revisited</article-title><source>Vaccine</source><volume>25</volume><issue>19</issue><year>2007</year><fpage>3752</fpage><lpage>3762</lpage><pub-id pub-id-type="pmid">17336431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.01.111</pub-id></element-citation></ref><ref id="b0140"><label>28</label><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name name-style="western"><surname>Lurie</surname><given-names>N.</given-names></name><name name-style="western"><surname>Saville</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hatchett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Halton</surname><given-names>J.</given-names></name></person-group><article-title>Developing Covid-19 vaccines at pandemic speed</article-title><source>N. Engl. J. Med.</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMp2005630</pub-id><pub-id pub-id-type="pmid">32227757</pub-id></element-citation></ref><ref id="b0145"><label>29</label><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name name-style="western"><surname>Hotez</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M.E.</given-names></name></person-group><article-title>Developing a low-cost and accessible COVID-19 vaccine for global</article-title><source>Health. Preprints</source><year>2020,</year><fpage>2020030464</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pntd.0008548</pub-id><pub-id pub-id-type="pmcid">PMC7390283</pub-id><pub-id pub-id-type="pmid">32726304</pub-id></element-citation></ref><ref id="b0150"><label>30</label><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name name-style="western"><surname>HogenEsch</surname><given-names>H.</given-names></name></person-group><article-title>Mechanisms of stimulation of the immune response by aluminum adjuvants</article-title><source>Vaccine</source><volume>20</volume><year>2002</year><fpage>S34</fpage><lpage>S39</lpage><pub-id pub-id-type="pmid">12184362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(02)00169-x</pub-id></element-citation></ref><ref id="b0155"><label>31</label><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name name-style="western"><surname>Ulanova</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tarkowski</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hahn-Zoric</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hanson</surname><given-names>L.&#197;.</given-names></name></person-group><article-title>The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism</article-title><source>Infect. Immun.</source><volume>69</volume><issue>2</issue><year>2001</year><fpage>1151</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">11160013</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.69.2.1151-1159.2001</pub-id><pub-id pub-id-type="pmcid">PMC97997</pub-id></element-citation></ref><ref id="b0160"><label>32</label><mixed-citation publication-type="other" id="h0160">Tomljenovic, L. and A Shaw, C., 2011. Aluminum vaccine adjuvants: are they safe?.&#160;Current Medicinal Chemistry,&#160;18(17), pp.2630-2637.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/092986711795933740</pub-id><pub-id pub-id-type="pmid">21568886</pub-id></mixed-citation></ref><ref id="b0165"><label>33</label><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name name-style="western"><surname>Kool</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soulli&#233;</surname><given-names>T.</given-names></name><name name-style="western"><surname>van Nimwegen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Willart</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Muskens</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoogsteden</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Hammad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lambrecht</surname><given-names>B.N.</given-names></name></person-group><article-title>Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells</article-title><source>J. Exp. Med.</source><volume>205</volume><issue>4</issue><year>2008</year><fpage>869</fpage><lpage>882</lpage><pub-id pub-id-type="pmid">18362170</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20071087</pub-id><pub-id pub-id-type="pmcid">PMC2292225</pub-id></element-citation></ref><ref id="b0170"><label>34</label><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name name-style="western"><surname>Takasuka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fujii</surname><given-names>H.</given-names></name><name name-style="western"><surname>Takahashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Kasai</surname><given-names>M.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Itamura</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ishii</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sakaguchi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ohnishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ohshima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashimoto</surname><given-names>S.I.</given-names></name></person-group><article-title>A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice</article-title><source>Int. Immunol.</source><volume>16</volume><issue>10</issue><year>2004</year><fpage>1423</fpage><lpage>1430</lpage><pub-id pub-id-type="pmid">15314040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/intimm/dxh143</pub-id><pub-id pub-id-type="pmcid">PMC7108621</pub-id></element-citation></ref><ref id="b0175"><label>35</label><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>F.</given-names></name></person-group><article-title>Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice</article-title><source>DNA Cell Biol.</source><volume>23</volume><issue>6</issue><year>2004</year><fpage>391</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">15231072</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/104454904323145272</pub-id></element-citation></ref><ref id="b0180"><label>36</label><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Si</surname><given-names>B.</given-names></name></person-group><article-title>Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine</article-title><source>Vaccine</source><volume>24</volume><issue>7</issue><year>2006</year><fpage>1028</fpage><lpage>1034</lpage><pub-id pub-id-type="pmid">16388880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.06.038</pub-id><pub-id pub-id-type="pmcid">PMC7115602</pub-id></element-citation></ref><ref id="b0185"><label>37</label><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.Q.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>W.</given-names></name></person-group><article-title>Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine</article-title><source>Virologica Sinica</source><volume>33</volume><issue>2</issue><year>2018</year><fpage>201</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">29541941</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12250-018-0009-2</pub-id><pub-id pub-id-type="pmcid">PMC6178114</pub-id></element-citation></ref><ref id="b0190"><label>38</label><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name></person-group><article-title>Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus</article-title><source>Emerging Microbes Infect.</source><volume>7</volume><issue>1</issue><year>2018</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41426-018-0056-7</pub-id><pub-id pub-id-type="pmcid">PMC5884803</pub-id><pub-id pub-id-type="pmid">29618723</pub-id></element-citation></ref><ref id="b0195"><label>39</label><element-citation publication-type="journal" id="h0195"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Algaissi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Garron</surname><given-names>T.</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Couch</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.K.</given-names></name></person-group><article-title>Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus</article-title><source>Human Vacc. Immunotherapeut.</source><volume>12</volume><issue>9</issue><year>2016</year><fpage>2351</fpage><lpage>2356</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2016.1177688</pub-id><pub-id pub-id-type="pmcid">PMC5027702</pub-id><pub-id pub-id-type="pmid">27269431</pub-id></element-citation></ref><ref id="b0200"><label>40</label><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name name-style="western"><surname>Bolles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Deming</surname><given-names>D.</given-names></name><name name-style="western"><surname>Long</surname><given-names>K.</given-names></name><name name-style="western"><surname>Agnihothram</surname><given-names>S.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>M.</given-names></name><name name-style="western"><surname>Funkhouser</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gralinski</surname><given-names>L.</given-names></name><name name-style="western"><surname>Totura</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge</article-title><source>J. Virol.</source><volume>85</volume><issue>23</issue><year>2011</year><fpage>12201</fpage><lpage>12215</lpage><pub-id pub-id-type="pmid">21937658</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.06048-11</pub-id><pub-id pub-id-type="pmcid">PMC3209347</pub-id></element-citation></ref><ref id="b0205"><label>41</label><mixed-citation publication-type="other" id="h0205">Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, Peters CJ, Couch RB. 2012. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0035421</pub-id><pub-id pub-id-type="pmcid">PMC3335060</pub-id><pub-id pub-id-type="pmid">22536382</pub-id></mixed-citation></ref><ref id="b0210"><label>42</label><mixed-citation publication-type="other" id="h0210">Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, Kase R, Sekiguchi S, Morita K, Hishima T, Suzuki H, Karamatsu K, Yasutomi Y, Shida H, Kidokoro M, Mizuno K, Matsushima K, Kohara M. 2008. Prior immunization with severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. JImmunol181:6337&#8211;6348.<pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.181.9.6337</pub-id><pub-id pub-id-type="pmid">18941225</pub-id></mixed-citation></ref><ref id="b0215"><label>43</label><element-citation publication-type="journal" id="h0215"><person-group person-group-type="author"><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name></person-group><article-title>The potential danger of suboptimal antibody responses in COVID-19</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><fpage>1</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">32317716</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0321-6</pub-id><pub-id pub-id-type="pmcid">PMC7187142</pub-id></element-citation></ref><ref id="b0220"><label>44</label><element-citation publication-type="journal" id="h0220"><person-group person-group-type="author"><name name-style="western"><surname>Deming</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sheahan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Heise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Yount</surname><given-names>B.</given-names></name><name name-style="western"><surname>Davis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sims</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suthar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Harkema</surname><given-names>J.</given-names></name><name name-style="western"><surname>Whitmore</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pickles</surname><given-names>R.</given-names></name><name name-style="western"><surname>West</surname><given-names>A.</given-names></name></person-group><article-title>Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants</article-title><source>PLoS Med.</source><volume>3</volume><issue>12</issue><year>2006</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pmed.0030525</pub-id><pub-id pub-id-type="pmcid">PMC1716185</pub-id><pub-id pub-id-type="pmid">17194199</pub-id></element-citation></ref><ref id="b0225"><label>45</label><element-citation publication-type="journal" id="h0225"><person-group person-group-type="author"><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>B.H.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.K.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology</article-title><source>J. Virol.</source><volume>89</volume><issue>6</issue><year>2015</year><fpage>2995</fpage><lpage>3007</lpage><pub-id pub-id-type="pmid">25520500</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02980-14</pub-id><pub-id pub-id-type="pmcid">PMC4337527</pub-id></element-citation></ref><ref id="b0230"><label>46</label><element-citation publication-type="journal" id="h0230"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Post</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chubet</surname><given-names>R.</given-names></name><name name-style="western"><surname>Holtz</surname><given-names>K.</given-names></name><name name-style="western"><surname>McPherson</surname><given-names>C.</given-names></name><name name-style="western"><surname>Petric</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>M.</given-names></name></person-group><article-title>A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice</article-title><source>Vaccine</source><volume>24</volume><issue>17</issue><year>2006</year><fpage>3624</fpage><lpage>3631</lpage><pub-id pub-id-type="pmid">16497416</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.01.059</pub-id><pub-id pub-id-type="pmcid">PMC7115485</pub-id></element-citation></ref><ref id="b0235"><label>47</label><element-citation publication-type="journal" id="h0235"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ulitzky</surname><given-names>L.</given-names></name><name name-style="western"><surname>Silberstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Viscidi</surname><given-names>R.</given-names></name></person-group><article-title>Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates</article-title><source>Viral Immunol.</source><volume>26</volume><issue>2</issue><year>2013</year><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">23573979</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/vim.2012.0076</pub-id><pub-id pub-id-type="pmcid">PMC3624630</pub-id></element-citation></ref><ref id="b0240"><label>48</label><element-citation publication-type="journal" id="h0240"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Kort</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.</given-names></name></person-group><article-title>Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV</article-title><source>Vaccine</source><volume>29</volume><issue>38</issue><year>2011</year><fpage>6606</fpage><lpage>6613</lpage><pub-id pub-id-type="pmid">21762752</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.06.111</pub-id><pub-id pub-id-type="pmcid">PMC3165014</pub-id></element-citation></ref><ref id="b0245"><label>49</label><element-citation publication-type="journal" id="h0245"><person-group person-group-type="author"><name name-style="western"><surname>Lokugamage</surname><given-names>K.G.</given-names></name><name name-style="western"><surname>Yoshikawa-Iwata</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ito</surname><given-names>N.</given-names></name><name name-style="western"><surname>Watts</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Wyde</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Newman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.K.</given-names></name><name name-style="western"><surname>Peters</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Makino</surname><given-names>S.</given-names></name></person-group><article-title>Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV</article-title><source>Vaccine</source><volume>26</volume><issue>6</issue><year>2008</year><fpage>797</fpage><lpage>808</lpage><pub-id pub-id-type="pmid">18191004</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.11.092</pub-id><pub-id pub-id-type="pmcid">PMC2267761</pub-id></element-citation></ref><ref id="b0250"><label>50</label><element-citation publication-type="journal" id="h0250"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Massare</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>M.B.</given-names></name></person-group><article-title>Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</article-title><source>Vaccine</source><volume>32</volume><issue>26</issue><year>2014</year><fpage>3169</fpage><lpage>3174</lpage><pub-id pub-id-type="pmid">24736006</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.04.016</pub-id><pub-id pub-id-type="pmcid">PMC4058772</pub-id></element-citation></ref><ref id="b0255"><label>51</label><element-citation publication-type="journal" id="h0255"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chag</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tricoche</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Seid</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Hudspeth</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.K.</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>M.E.</given-names></name></person-group><article-title>Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate</article-title><source>Human Vac. Immunotherapeutics</source><volume>10</volume><issue>3</issue><year>2014</year><fpage>648</fpage><lpage>658</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.27464</pub-id><pub-id pub-id-type="pmcid">PMC4130269</pub-id><pub-id pub-id-type="pmid">24355931</pub-id></element-citation></ref><ref id="b0260"><label>52</label><element-citation publication-type="journal" id="h0260"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name></person-group><article-title>MERS-CoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques</article-title><source>Oncotarget</source><volume>8</volume><issue>8</issue><year>2017</year><fpage>12686</fpage><pub-id pub-id-type="pmid">27050368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/oncotarget.8475</pub-id><pub-id pub-id-type="pmcid">PMC5355045</pub-id></element-citation></ref><ref id="b0265"><label>53</label><element-citation publication-type="journal" id="h0265"><person-group person-group-type="author"><name name-style="western"><surname>Lan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>C.</given-names></name></person-group><article-title>Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge</article-title><source>EBioMedicine</source><volume>2</volume><issue>10</issue><year>2015</year><fpage>1438</fpage><lpage>1446</lpage><pub-id pub-id-type="pmid">26629538</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ebiom.2015.08.031</pub-id><pub-id pub-id-type="pmcid">PMC4634622</pub-id></element-citation></ref><ref id="b0270"><label>54</label><element-citation publication-type="book" id="h0270"><person-group person-group-type="author"><name name-style="western"><surname>Kommareddy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Singh</surname><given-names>M.</given-names></name><name name-style="western"><surname>O'Hagan</surname><given-names>D.T.</given-names></name></person-group><chapter-title>MF59: a safe and potent adjuvant for human use</chapter-title><source>Immunopotentiators in Modern Vaccines</source><year>2017</year><publisher-name>Academic Press</publisher-name><fpage>249</fpage><lpage>263</lpage></element-citation></ref><ref id="b0275"><label>55</label><element-citation publication-type="journal" id="h0275"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name></person-group><article-title>MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection</article-title><source>Expert Rev. Vaccines</source><volume>6</volume><issue>5</issue><year>2007</year><fpage>699</fpage><lpage>710</lpage><pub-id pub-id-type="pmid">17931151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.6.5.699</pub-id></element-citation></ref><ref id="b0280"><label>56</label><element-citation publication-type="journal" id="h0280"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>De Gregorio</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G.</given-names></name></person-group><article-title>MF59 adjuvant: the best insurance against influenza strain diversity</article-title><source>Expert Rev Vaccines.</source><volume>10</volume><year>2011</year><fpage>447</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1586/erv.11.23</pub-id><pub-id pub-id-type="pmid">21506643</pub-id></element-citation></ref><ref id="b0285"><label>57</label><element-citation publication-type="journal" id="h0285"><person-group person-group-type="author"><name name-style="western"><surname>Galli</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hancock</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hoschler</surname><given-names>K.</given-names></name><name name-style="western"><surname>DeVos</surname><given-names>J.</given-names></name><name name-style="western"><surname>Praus</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bardelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Malzone</surname><given-names>C.</given-names></name><name name-style="western"><surname>Castellino</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gentile</surname><given-names>C.</given-names></name><name name-style="western"><surname>McNally</surname><given-names>T.</given-names></name></person-group><article-title>Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine</article-title><source>Proc. Natl. Acad Sci. USA</source><volume>106</volume><year>2009</year><fpage>7962</fpage><lpage>7967</lpage><pub-id pub-id-type="doi">10.1073/pnas.0903181106</pub-id><pub-id pub-id-type="pmid">19416838</pub-id><pub-id pub-id-type="pmcid">PMC2674105</pub-id></element-citation></ref><ref id="b0290"><label>58</label><element-citation publication-type="journal" id="h0290"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.M.</given-names></name></person-group><article-title>Immunology and efficacy of MF59-adjuvanted vaccines</article-title><source>Human Vacc. Immunotherapeut.</source><volume>14</volume><issue>12</issue><year>2018</year><fpage>3041</fpage><lpage>3045</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2018.1495301</pub-id><pub-id pub-id-type="pmcid">PMC6343625</pub-id><pub-id pub-id-type="pmid">30015572</pub-id></element-citation></ref><ref id="b0295"><label>59</label><element-citation publication-type="journal" id="h0295"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Jung</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Denning</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>S.M.</given-names></name></person-group><article-title>Effects of MF59 adjuvant on induction of isotype-switched IgG antibodies and protection after immunization with T-dependent influenza virus vaccine in the absence of CD4+ T cells</article-title><source>J. Virol.</source><volume>90</volume><year>2016</year><fpage>6976</fpage><lpage>6988</lpage><pub-id pub-id-type="doi">10.1128/JVI.00339-16</pub-id><pub-id pub-id-type="pmid">27226368</pub-id><pub-id pub-id-type="pmcid">PMC4944285</pub-id></element-citation></ref><ref id="b0300"><label>60</label><element-citation publication-type="journal" id="h0300"><person-group person-group-type="author"><name name-style="western"><surname>Stadler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kolesnikova</surname><given-names>L.</given-names></name><name name-style="western"><surname>Klenk</surname><given-names>H.D.</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rappuoli</surname><given-names>R.</given-names></name><name name-style="western"><surname>Abrignani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>SARS vaccine protective in mice</article-title><source>Emerg. Infect. Dis.</source><volume>11</volume><issue>8</issue><year>2005</year><fpage>1312</fpage><pub-id pub-id-type="pmid">16110580</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3201/eid1108.041003</pub-id><pub-id pub-id-type="pmcid">PMC3320494</pub-id></element-citation></ref><ref id="b0305"><label>61</label><element-citation publication-type="journal" id="h0305"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.K.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus</article-title><source>Human Vacc. Immunotherapeut.</source><volume>11</volume><issue>5</issue><year>2015</year><fpage>1244</fpage><lpage>1250</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1021527</pub-id><pub-id pub-id-type="pmcid">PMC4514392</pub-id><pub-id pub-id-type="pmid">25874632</pub-id></element-citation></ref><ref id="b0310"><label>62</label><element-citation publication-type="journal" id="h0310"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Son</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Sung</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>J.E.</given-names></name></person-group><article-title>Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>1093</fpage><pub-id pub-id-type="pmid">29868035</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2018.01093</pub-id><pub-id pub-id-type="pmcid">PMC5966535</pub-id></element-citation></ref><ref id="b0315"><label>63</label><element-citation publication-type="journal" id="h0315"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.K.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name></person-group><article-title>Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection</article-title><source>Human Vacc. Immunotherapeut.</source><volume>13</volume><issue>7</issue><year>2017</year><fpage>1615</fpage><lpage>1624</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2017.1296994</pub-id><pub-id pub-id-type="pmcid">PMC5512770</pub-id><pub-id pub-id-type="pmid">28277821</pub-id></element-citation></ref><ref id="b0320"><label>64</label><element-citation publication-type="journal" id="h0320"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>C.T.K.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lanying</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection</article-title><source>Virology</source><volume>499</volume><year>2016</year><fpage>375</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">27750111</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2016.10.005</pub-id><pub-id pub-id-type="pmcid">PMC5167628</pub-id></element-citation></ref><ref id="b0325"><label>65</label><element-citation publication-type="journal" id="h0325"><person-group person-group-type="author"><name name-style="western"><surname>van Doorn</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Huckriede</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hak</surname><given-names>E.</given-names></name></person-group><article-title>Safety and tolerability evaluation of the use of Montanide ISA&#8482; 51 as vaccine adjuvant: a systematic review</article-title><source>Human Vacc. Immunotherapeutics</source><volume>12</volume><issue>1</issue><year>2016</year><fpage>159</fpage><lpage>169</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2015.1071455</pub-id><pub-id pub-id-type="pmcid">PMC4962750</pub-id><pub-id pub-id-type="pmid">26378866</pub-id></element-citation></ref><ref id="b0330"><label>66</label><element-citation publication-type="journal" id="h0330"><person-group person-group-type="author"><name name-style="western"><surname>Aucouturier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dupuis</surname><given-names>L.</given-names></name><name name-style="western"><surname>Deville</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ascarateil</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ganne</surname><given-names>V.</given-names></name></person-group><article-title>Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines</article-title><source>Expert Rev. Vaccines</source><volume>1</volume><issue>1</issue><year>2002</year><fpage>111</fpage><lpage>118</lpage><pub-id pub-id-type="pmid">12908518</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.1.1.111</pub-id></element-citation></ref><ref id="b0335"><label>67</label><element-citation publication-type="journal" id="h0335"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Oakley</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kuppusamy</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Taye</surname><given-names>A.</given-names></name><name name-style="western"><surname>Krieg</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Stowers</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Kaslow</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Hoffman</surname><given-names>S.L.</given-names></name></person-group><article-title>CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine</article-title><source>Infect. Immun.</source><volume>72</volume><issue>2</issue><year>2004</year><fpage>949</fpage><lpage>957</lpage><pub-id pub-id-type="pmid">14742540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.72.2.949-957.2004</pub-id><pub-id pub-id-type="pmcid">PMC321633</pub-id></element-citation></ref><ref id="b0340"><label>68</label><element-citation publication-type="journal" id="h0340"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>McElrath</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Keefer</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Rybczyk</surname><given-names>K.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinhold</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Ottinger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ferarri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Montefiori</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Stablein</surname><given-names>D.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>C.</given-names></name></person-group><article-title>Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity</article-title><source>PLoS ONE</source><volume>5</volume><issue>8</issue><year>2010</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0011995</pub-id><pub-id pub-id-type="pmcid">PMC2919382</pub-id><pub-id pub-id-type="pmid">20706632</pub-id></element-citation></ref><ref id="b0345"><label>69</label><element-citation publication-type="journal" id="h0345"><person-group person-group-type="author"><name name-style="western"><surname>Diefenbach</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Gnjatic</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sabbatini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Aghajanian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Spriggs</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Iasonos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dupont</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pezzulli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jungbluth</surname><given-names>A.A.</given-names></name></person-group><article-title>Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission</article-title><source>Clin. Cancer Res.</source><volume>14</volume><issue>9</issue><year>2008</year><fpage>2740</fpage><lpage>2748</lpage><pub-id pub-id-type="pmid">18451240</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-07-4619</pub-id></element-citation></ref><ref id="b0350"><label>70</label><element-citation publication-type="journal" id="h0350"><person-group person-group-type="author"><name name-style="western"><surname>Atsmon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kate-Ilovitz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shaikevich</surname><given-names>D.</given-names></name><name name-style="western"><surname>Singer</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Volokhov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Haim</surname><given-names>K.Y.</given-names></name><name name-style="western"><surname>Ben-Yedidia</surname><given-names>T.</given-names></name></person-group><article-title>Safety and immunogenicity of multimeric-001&#8212;a novel universal influenza vaccine</article-title><source>J. Clin. Immunol.</source><volume>32</volume><issue>3</issue><year>2012</year><fpage>595</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">22318394</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10875-011-9632-5</pub-id></element-citation></ref><ref id="b0355"><label>71</label><element-citation publication-type="journal" id="h0355"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Lien</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Chi</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lian</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Hsieh</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Chong</surname><given-names>P.</given-names></name></person-group><article-title>Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates</article-title><source>Vaccine</source><volume>24</volume><issue>16</issue><year>2006</year><fpage>3100</fpage><lpage>3108</lpage><pub-id pub-id-type="pmid">16494977</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.01.058</pub-id><pub-id pub-id-type="pmcid">PMC7115648</pub-id></element-citation></ref><ref id="b0360"><label>72</label><element-citation publication-type="journal" id="h0360"><person-group person-group-type="author"><name name-style="western"><surname>Lien</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Shih</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Tsai</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Leng</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Chou</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.M.A.</given-names></name></person-group><article-title>Identification of synthetic vaccine candidates against SARS CoV infection</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>358</volume><issue>3</issue><year>2007</year><fpage>716</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">17506989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2007.04.164</pub-id><pub-id pub-id-type="pmcid">PMC7092873</pub-id></element-citation></ref><ref id="b0365"><label>73</label><element-citation publication-type="journal" id="h0365"><person-group person-group-type="author"><name name-style="western"><surname>Azizi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aucoin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tadesse</surname><given-names>H.</given-names></name><name name-style="western"><surname>Frost</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ghorbani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soare</surname><given-names>C.</given-names></name><name name-style="western"><surname>Naas</surname><given-names>T.</given-names></name><name name-style="western"><surname>Diaz-Mitoma</surname><given-names>F.</given-names></name></person-group><article-title>A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses</article-title><source>Genetic Vacc. Therapy</source><volume>3</volume><issue>1</issue><year>2005</year><fpage>7</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1479-0556-3-7</pub-id><pub-id pub-id-type="pmcid">PMC1249587</pub-id><pub-id pub-id-type="pmid">16115319</pub-id></element-citation></ref><ref id="b0370"><label>74</label><element-citation publication-type="journal" id="h0370"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Poon</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Debnath</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Identification of receptor-binding domain in S protein of the novel human coronavirus MERS-CoV as an essential target for vaccine development</article-title><source>J. Virol.</source><year>2013</year><comment>pp.JVI-01048</comment><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01048-13</pub-id><pub-id pub-id-type="pmcid">PMC3754113</pub-id><pub-id pub-id-type="pmid">23824801</pub-id></element-citation></ref><ref id="b0375"><label>75</label><element-citation publication-type="journal" id="h0375"><person-group person-group-type="author"><name name-style="western"><surname>Didierlaurent</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Laup&#232;ze</surname><given-names>B.</given-names></name><name name-style="western"><surname>Di Pasquale</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hergli</surname><given-names>N.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gar&#231;on</surname><given-names>N.</given-names></name></person-group><article-title>Adjuvant system AS01: helping to overcome the challenges of modern vaccines</article-title><source>Expert Rev. Vaccines</source><volume>16</volume><issue>1</issue><year>2017</year><fpage>55</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">27448771</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/14760584.2016.1213632</pub-id></element-citation></ref><ref id="b0380"><label>76</label><element-citation publication-type="journal" id="h0380"><person-group person-group-type="author"><name name-style="western"><surname>Coccia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Collignon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Herv&#233;</surname><given-names>C.</given-names></name><name name-style="western"><surname>Chalon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Welsby</surname><given-names>I.</given-names></name><name name-style="western"><surname>Detienne</surname><given-names>S.</given-names></name><name name-style="western"><surname>van Helden</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Dutta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Genito</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Waters</surname><given-names>N.C.</given-names></name><name name-style="western"><surname>Van Deun</surname><given-names>K.</given-names></name></person-group><article-title>Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN&#947; response promoting vaccine immunogenicity</article-title><source>npj Vaccines</source><volume>2</volume><issue>1</issue><year>2017</year><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">29263880</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-017-0027-3</pub-id><pub-id pub-id-type="pmcid">PMC5627273</pub-id></element-citation></ref><ref id="b0385"><label>77</label><element-citation publication-type="journal" id="h0385"><person-group person-group-type="author"><name name-style="western"><surname>Bisht</surname><given-names>H.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Moss</surname><given-names>B.</given-names></name></person-group><article-title>Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein</article-title><source>Virology</source><volume>334</volume><issue>2</issue><year>2005</year><fpage>160</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">15780866</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.virol.2005.01.042</pub-id><pub-id pub-id-type="pmcid">PMC7111832</pub-id></element-citation></ref><ref id="b0390"><label>78</label><element-citation publication-type="journal" id="h0390"><person-group person-group-type="author"><name name-style="western"><surname>Rts</surname><given-names>S.C.T.P.</given-names></name></person-group><article-title>Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial</article-title><source>The Lancet</source><volume>386</volume><issue>9988</issue><year>2015</year><fpage>31</fpage><lpage>45</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(15)60721-8</pub-id><pub-id pub-id-type="pmcid">PMC5626001</pub-id><pub-id pub-id-type="pmid">25913272</pub-id></element-citation></ref><ref id="b0395"><label>79</label><element-citation publication-type="journal" id="h0395"><person-group person-group-type="author"><name name-style="western"><surname>Chlibek</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pauksens</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rombo</surname><given-names>L.</given-names></name><name name-style="western"><surname>van Rijckevorsel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Richardus</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Plassmann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Catteau</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lal</surname><given-names>H.</given-names></name><name name-style="western"><surname>Heineman</surname><given-names>T.C.</given-names></name></person-group><article-title>Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults</article-title><source>Vaccine</source><volume>34</volume><issue>6</issue><year>2016</year><fpage>863</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">26432913</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.09.073</pub-id></element-citation></ref><ref id="b0400"><label>80</label><element-citation publication-type="journal" id="h0400"><person-group person-group-type="author"><name name-style="western"><surname>Van Braeckel</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bourguignon</surname><given-names>P.</given-names></name><name name-style="western"><surname>Koutsoukos</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clement</surname><given-names>F.</given-names></name><name name-style="western"><surname>Janssens</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carletti</surname><given-names>I.</given-names></name><name name-style="western"><surname>Collard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Demoiti&#233;</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Voss</surname><given-names>G.</given-names></name><name name-style="western"><surname>Leroux-Roels</surname><given-names>G.</given-names></name><name name-style="western"><surname>McNally</surname><given-names>L.</given-names></name></person-group><article-title>An adjuvanted polyprotein HIV-1 vaccine induces polyfunctional cross-reactive CD4+ T cell responses in seronegative volunteers</article-title><source>Clin. Infect. Dis.</source><volume>52</volume><issue>4</issue><year>2011</year><fpage>522</fpage><lpage>531</lpage><pub-id pub-id-type="pmid">21208909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciq160</pub-id><pub-id pub-id-type="pmcid">PMC3060898</pub-id></element-citation></ref><ref id="b0405"><label>81</label><mixed-citation publication-type="other" id="h0405">Leroux-Roels, I., Forgus, S., De Boever, F., Clement, F., Demoiti&#233;, M.A., Mettens, P., Moris, P., Ledent, E., Leroux-Roels, G., Ofori-Anyinam, O. and M72 Study Group, 2013. Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.&#160;Vaccine,&#160;31(17), pp.2196-2206.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.05.035</pub-id><pub-id pub-id-type="pmid">22643213</pub-id></mixed-citation></ref><ref id="b0410"><label>82</label><element-citation publication-type="journal" id="h0410"><person-group person-group-type="author"><name name-style="western"><surname>Roberts</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamirande</surname><given-names>E.W.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Baras</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goossens</surname><given-names>G.</given-names></name><name name-style="western"><surname>Knott</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Vassilev</surname><given-names>V.</given-names></name><name name-style="western"><surname>Subbarao</surname><given-names>K.</given-names></name></person-group><article-title>Immunogenicity and protective efficacy in mice and hamsters of a &#946;-propiolactone inactivated whole virus SARS-CoV vaccine</article-title><source>Viral Immunol.</source><volume>23</volume><issue>5</issue><year>2010</year><fpage>509</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">20883165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/vim.2010.0028</pub-id><pub-id pub-id-type="pmcid">PMC2967819</pub-id></element-citation></ref><ref id="b0415"><label>83</label><element-citation publication-type="journal" id="h0415"><person-group person-group-type="author"><name name-style="western"><surname>Lobigs</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pavy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Lobigs</surname><given-names>P.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>P.</given-names></name><name name-style="western"><surname>Komiya</surname><given-names>T.</given-names></name><name name-style="western"><surname>Toriniwa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses</article-title><source>J. General Virol.</source><volume>91</volume><issue>Pt 6</issue><year>2010</year><fpage>1407</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1099/vir.0.019190-0</pub-id><pub-id pub-id-type="pmcid">PMC2888167</pub-id><pub-id pub-id-type="pmid">20130134</pub-id></element-citation></ref><ref id="b0420"><label>84</label><element-citation publication-type="journal" id="h0420"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>P.D.</given-names></name></person-group><article-title>Advax&#8482;, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety</article-title><source>Vaccine</source><volume>33</volume><issue>44</issue><year>2015</year><fpage>5920</fpage><lpage>5926</lpage><pub-id pub-id-type="pmid">26407920</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.09.030</pub-id><pub-id pub-id-type="pmcid">PMC4639457</pub-id></element-citation></ref><ref id="b0425"><label>85</label><element-citation publication-type="journal" id="h0425"><person-group person-group-type="author"><name name-style="western"><surname>Cooper</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Delta inulin: a novel, immunologically active, stable packing structure comprising &#946;-D-[2&#8594; 1] poly (fructo-furanosyl) &#945;-D-glucose polymers</article-title><source>Glycobiology</source><volume>21</volume><issue>5</issue><year>2011</year><fpage>595</fpage><lpage>606</lpage><pub-id pub-id-type="pmid">21147758</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/glycob/cwq201</pub-id><pub-id pub-id-type="pmcid">PMC3106373</pub-id></element-citation></ref><ref id="b0430"><label>86</label><element-citation publication-type="journal" id="h0430"><person-group person-group-type="author"><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saade</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Advax&#8482;, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses</article-title><source>Vaccine</source><volume>30</volume><issue>36</issue><year>2012</year><fpage>5373</fpage><lpage>5381</lpage><pub-id pub-id-type="pmid">22728225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2012.06.021</pub-id><pub-id pub-id-type="pmcid">PMC3401346</pub-id></element-citation></ref><ref id="b0435"><label>87</label><element-citation publication-type="journal" id="h0435"><person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K.</given-names></name></person-group><article-title>Toll-like receptor signalling</article-title><source>Nat. Rev. Immunol.</source><volume>4</volume><issue>7</issue><year>2004</year><fpage>499</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">15229469</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nri1391</pub-id></element-citation></ref><ref id="b0440"><label>88</label><element-citation publication-type="journal" id="h0440"><person-group person-group-type="author"><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Windish</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Use of defined TLR ligands as adjuvants within human vaccines</article-title><source>Immunol. Rev.</source><volume>239</volume><issue>1</issue><year>2011</year><fpage>178</fpage><lpage>196</lpage><pub-id pub-id-type="pmid">21198672</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1600-065X.2010.00978.x</pub-id><pub-id pub-id-type="pmcid">PMC5872835</pub-id></element-citation></ref><ref id="b0445"><label>89</label><element-citation publication-type="journal" id="h0445"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Deb</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chellappa</surname><given-names>M.M.</given-names></name></person-group><article-title>Toll-like receptor-based adjuvants: enhancing the immune response to vaccines against infectious diseases of chicken</article-title><source>Expert Rev. Vacc.</source><volume>13</volume><issue>7</issue><year>2014</year><fpage>909</fpage><lpage>925</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/14760584.2014.920236</pub-id><pub-id pub-id-type="pmid">24855906</pub-id></element-citation></ref><ref id="b0450"><label>90</label><element-citation publication-type="journal" id="h0450"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Bajwa</surname><given-names>P.</given-names></name><name name-style="western"><surname>Deb</surname><given-names>R.</given-names></name><name name-style="western"><surname>Chellappa</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>S.</given-names></name></person-group><article-title>Flagellin a toll-like receptor 5 agonist as an adjuvant in chicken vaccines</article-title><source>Clin. Vaccine Immunol.</source><volume>21</volume><issue>3</issue><year>2014</year><fpage>261</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">24451328</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/CVI.00669-13</pub-id><pub-id pub-id-type="pmcid">PMC3957660</pub-id></element-citation></ref><ref id="b0455"><label>91</label><element-citation publication-type="journal" id="h0455"><person-group person-group-type="author"><name name-style="western"><surname>Iwata-Yoshikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Uda</surname><given-names>A.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>T.</given-names></name><name name-style="western"><surname>Tsunetsugu-Yokota</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sato</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Morikawa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tashiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sata</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hasegawa</surname><given-names>H.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>N.</given-names></name></person-group><article-title>Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine</article-title><source>J. Virol.</source><volume>88</volume><issue>15</issue><year>2014</year><fpage>8597</fpage><lpage>8614</lpage><pub-id pub-id-type="pmid">24850731</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00983-14</pub-id><pub-id pub-id-type="pmcid">PMC4135953</pub-id></element-citation></ref><ref id="b0460"><label>92</label><element-citation publication-type="journal" id="h0460"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wohlford-Lenane</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lane</surname><given-names>T.E.</given-names></name><name name-style="western"><surname>McCray</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Intranasal treatment with poly (I&#183;C) protects aged mice from lethal respiratory virus infections</article-title><source>J. Virol.</source><volume>86</volume><issue>21</issue><year>2012</year><fpage>11416</fpage><lpage>11424</lpage><pub-id pub-id-type="pmid">22915814</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01410-12</pub-id><pub-id pub-id-type="pmcid">PMC3486278</pub-id></element-citation></ref><ref id="b0465"><label>93</label><element-citation publication-type="journal" id="h0465"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>N.S.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>L.W.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y.M.</given-names></name></person-group><article-title>Intranasal immunization with inactivated SARS-CoV (SARS-associated coronavirus) induced local and serum antibodies in mice</article-title><source>Vaccine</source><volume>23</volume><issue>7</issue><year>2005</year><fpage>924</fpage><lpage>931</lpage><pub-id pub-id-type="pmid">15603894</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2004.07.031</pub-id><pub-id pub-id-type="pmcid">PMC7115388</pub-id></element-citation></ref><ref id="b0470"><label>94</label><element-citation publication-type="journal" id="h0470"><person-group person-group-type="author"><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tien</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.</given-names></name></person-group><article-title>Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine</article-title><source>Viral Immunol.</source><volume>21</volume><issue>1</issue><year>2008</year><fpage>27</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">18355120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/vim.2007.0079</pub-id></element-citation></ref><ref id="b0475"><label>95</label><element-citation publication-type="journal" id="h0475"><person-group person-group-type="author"><name name-style="western"><surname>Gai</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>H.M.</given-names></name></person-group><article-title>PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV</article-title><source>Virologica Sinica</source><volume>26</volume><issue>2</issue><year>2011</year><fpage>81</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">21468931</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12250-011-3183-z</pub-id><pub-id pub-id-type="pmcid">PMC7091335</pub-id></element-citation></ref><ref id="b0480"><label>96</label><element-citation publication-type="journal" id="h0480"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Li</surname><given-names>N.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name></person-group><article-title>Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice</article-title><source>Antiviral Res.</source><volume>140</volume><year>2017</year><fpage>55</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">28040513</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.antiviral.2016.12.019</pub-id><pub-id pub-id-type="pmcid">PMC7113847</pub-id></element-citation></ref><ref id="b0485"><label>97</label><element-citation publication-type="journal" id="h0485"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C.</given-names></name></person-group><article-title>The immune responses of HLA-A* 0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI: C and R848</article-title><source>Vaccine</source><volume>29</volume><issue>38</issue><year>2011</year><fpage>6670</fpage><lpage>6678</lpage><pub-id pub-id-type="pmid">21745520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.06.100</pub-id><pub-id pub-id-type="pmcid">PMC7115397</pub-id></element-citation></ref><ref id="b0490"><label>98</label><element-citation publication-type="journal" id="h0490"><person-group person-group-type="author"><name name-style="western"><surname>Zakhartchouk</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Sharon</surname><given-names>C.</given-names></name><name name-style="western"><surname>Satkunarajah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auperin</surname><given-names>T.</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mutwiri</surname><given-names>G.</given-names></name><name name-style="western"><surname>Petric</surname><given-names>M.</given-names></name><name name-style="western"><surname>See</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Brunham</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Finlay</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>C.</given-names></name></person-group><article-title>Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine</article-title><source>Vaccine</source><volume>25</volume><issue>1</issue><year>2007</year><fpage>136</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">16919855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2006.06.084</pub-id><pub-id pub-id-type="pmcid">PMC7115608</pub-id></element-citation></ref><ref id="b0495"><label>99</label><element-citation publication-type="journal" id="h0495"><person-group person-group-type="author"><name name-style="western"><surname>Jiaming</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yanfeng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Yawei</surname><given-names>H.</given-names></name><name name-style="western"><surname>Linlin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baoying</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jinghua</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Chuan</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wenjie</surname><given-names>T.</given-names></name></person-group><article-title>The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection</article-title><source>Vaccine</source><volume>35</volume><issue>1</issue><year>2017</year><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">27899228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.11.064</pub-id><pub-id pub-id-type="pmcid">PMC7115548</pub-id></element-citation></ref><ref id="b0500"><label>100</label><element-citation publication-type="journal" id="h0500"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Barker</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Parhar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Heck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>S.</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name></person-group><article-title>Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells</article-title><source>J. Immunol.</source><volume>182</volume><issue>7</issue><year>2009</year><fpage>4005</fpage><lpage>4016</lpage><pub-id pub-id-type="pmid">19299698</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0800531</pub-id></element-citation></ref><ref id="b0505"><label>101</label><element-citation publication-type="journal" id="h0505"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Tawe</surname><given-names>W.</given-names></name><name name-style="western"><surname>Leon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Oksov</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group><article-title>Ov-ASP-1, the Onchocerca volvulus homologue of the activation associated secreted protein family is immunostimulatory and can induce protective anti-larval immunity</article-title><source>Parasite Immunol.</source><volume>26</volume><issue>1</issue><year>2004</year><fpage>53</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">15198646</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.0141-9838.2004.00685.x</pub-id></element-citation></ref><ref id="b0510"><label>102</label><mixed-citation publication-type="other" id="h0510">Wang, J., Tricoche, N., Du, L., Hunter, M., Zhan, B., Goud, G., Didier, E.S., Liu, J., Lu, L., Marx, P.A. and Jiang, S., 2012. The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PloS one, 7(5).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0037019</pub-id><pub-id pub-id-type="pmcid">PMC3355165</pub-id><pub-id pub-id-type="pmid">22615877</pub-id></mixed-citation></ref><ref id="b0515"><label>103</label><element-citation publication-type="journal" id="h0515"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines</article-title><source>Vaccine</source><volume>26</volume><issue>39</issue><year>2008</year><fpage>5022</fpage><lpage>5029</lpage><pub-id pub-id-type="pmid">18675867</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.07.028</pub-id><pub-id pub-id-type="pmcid">PMC2597511</pub-id></element-citation></ref><ref id="b0520"><label>104</label><element-citation publication-type="journal" id="h0520"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sui</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kou</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B.J.</given-names></name></person-group><article-title>An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses</article-title><source>Virology J.</source><volume>7</volume><issue>1</issue><year>2010</year><fpage>9</fpage><pub-id pub-id-type="pmid">20082709</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1743-422X-7-9</pub-id><pub-id pub-id-type="pmcid">PMC2823673</pub-id></element-citation></ref><ref id="b0525"><label>105</label><element-citation publication-type="journal" id="h0525"><person-group person-group-type="author"><name name-style="western"><surname>MacDonald</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name></person-group><article-title>rOv-ASP-1, a recombinant secreted protein of the helminth Onchocerca volvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens</article-title><source>Vaccine</source><volume>23</volume><issue>26</issue><year>2005</year><fpage>3446</fpage><lpage>3452</lpage><pub-id pub-id-type="pmid">15837368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2005.01.098</pub-id><pub-id pub-id-type="pmcid">PMC7115491</pub-id></element-citation></ref><ref id="b0530"><label>106</label><element-citation publication-type="journal" id="h0530"><person-group person-group-type="author"><name name-style="western"><surname>Plante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Torossian</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gauthier</surname><given-names>J.</given-names></name><name name-style="western"><surname>St-F&#233;lix</surname><given-names>N.</given-names></name><name name-style="western"><surname>White</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.S.</given-names></name></person-group><article-title>Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge</article-title><source>Vaccine</source><volume>20</volume><issue>1&#8211;2</issue><year>2001</year><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="pmid">11567767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0264-410x(01)00268-7</pub-id></element-citation></ref><ref id="b0535"><label>107</label><element-citation publication-type="journal" id="h0535"><person-group person-group-type="author"><name name-style="western"><surname>Jones</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cyr</surname><given-names>S.</given-names></name><name name-style="western"><surname>Allard</surname><given-names>F.</given-names></name><name name-style="western"><surname>Bellerose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.H.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.S.</given-names></name></person-group><article-title>Protollin&#8482;: a novel adjuvant for intranasal vaccines</article-title><source>Vaccine</source><volume>22</volume><issue>27&#8211;28</issue><year>2004</year><fpage>3691</fpage><lpage>3697</lpage><pub-id pub-id-type="pmid">15315848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2004.03.035</pub-id></element-citation></ref><ref id="b0540"><label>108</label><element-citation publication-type="journal" id="h0540"><person-group person-group-type="author"><name name-style="western"><surname>Shalaby</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Jo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nakada</surname><given-names>E.</given-names></name><name name-style="western"><surname>Allard-Coutu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tsuchiya</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hirota</surname><given-names>N.</given-names></name><name name-style="western"><surname>Qureshi</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Maghni</surname><given-names>K.</given-names></name><name name-style="western"><surname>Rioux</surname><given-names>C.R.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>J.G.</given-names></name></person-group><article-title>ICOS-expressing CD4 T cells induced via TLR4 in the nasal mucosa are capable of inhibiting experimental allergic asthma</article-title><source>J. Immunol.</source><volume>189</volume><issue>6</issue><year>2012</year><fpage>2793</fpage><lpage>2804</lpage><pub-id pub-id-type="pmid">22908333</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1201194</pub-id></element-citation></ref><ref id="b0545"><label>109</label><element-citation publication-type="journal" id="h0545"><person-group person-group-type="author"><name name-style="western"><surname>Mallett</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Kaminski</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Larsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>N.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.H.</given-names></name></person-group><article-title>Intransal or intragastric immunization with proteosome-Shigella lipopolysaccharide vaccines protects against lethal pneumonia in a murine model of Shigella infection</article-title><source>Infect. Immun.</source><volume>63</volume><issue>6</issue><year>1995</year><fpage>2382</fpage><lpage>2386</lpage><pub-id pub-id-type="pmid">7768627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/iai.63.6.2382-2386.1995</pub-id><pub-id pub-id-type="pmcid">PMC173317</pub-id></element-citation></ref><ref id="b0550"><label>110</label><element-citation publication-type="journal" id="h0550"><person-group person-group-type="author"><name name-style="western"><surname>Fries</surname><given-names>L.F.</given-names></name><name name-style="western"><surname>Montemarano</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Mallett</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>D.N.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.H.</given-names></name></person-group><article-title>Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults</article-title><source>Infect. Immun.</source><volume>69</volume><issue>7</issue><year>2001</year><fpage>4545</fpage><lpage>4553</lpage><pub-id pub-id-type="pmid">11401998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.69.7.4545-4553.2001</pub-id><pub-id pub-id-type="pmcid">PMC98531</pub-id></element-citation></ref><ref id="b0555"><label>111</label><mixed-citation publication-type="other" id="h0555">Lambkin-Williams, R., Gelder, C., Broughton, R., Mallett, C.P., Gilbert, A.S., Mann, A., He, D., Oxford, J.S. and Burt, D., 2016. An intranasal proteosome-adjuvanted trivalent influenza vaccine is safe, immunogenic &amp; efficacious in the human viral influenza challenge model. Serum IgG &amp; mucosal IgA are important correlates of protection against illness associated with infection. PloS one, 11(12).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0163089</pub-id><pub-id pub-id-type="pmcid">PMC5179046</pub-id><pub-id pub-id-type="pmid">28005959</pub-id></mixed-citation></ref><ref id="b0560"><label>112</label><element-citation publication-type="journal" id="h0560"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kenney</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Barnard</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.H.</given-names></name></person-group><article-title>Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice</article-title><source>Vaccine</source><volume>25</volume><issue>34</issue><year>2007</year><fpage>6334</fpage><lpage>6340</lpage><pub-id pub-id-type="pmid">17640780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2007.06.017</pub-id><pub-id pub-id-type="pmcid">PMC7115497</pub-id></element-citation></ref><ref id="b0565"><label>113</label><mixed-citation publication-type="other" id="h0565">Gao, Q., Bao, L., Mao, H., Wang, L., Xu, K., Yang, M., Li, Y., Zhu, L., Wang, N., Lv, Z. and Gao, H., 2020. Development of an inactivated vaccine candidate for SARS-CoV-2.&#160;Science.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc1932</pub-id><pub-id pub-id-type="pmcid">PMC7202686</pub-id><pub-id pub-id-type="pmid">32376603</pub-id></mixed-citation></ref><ref id="b0570"><label>114</label><mixed-citation publication-type="other" id="h0570">Ren, W., Sun, H., Gao, G.F., Chen, J., Sun, S., Zhao, R., Gao, G., Hu, Y., Zhao, G., Chen, Y. and Jin, X., 2020. Recombinant SARS-CoV-2 spike S1-Fc fusion protein induced high levels of neutralizing responses in nonhuman primates.&#160;bioRxiv. doi:&#160;<pub-id pub-id-type="doi">10.1101/2020.04.21.052209</pub-id>.<pub-id pub-id-type="pmcid">PMC7311893</pub-id><pub-id pub-id-type="pmid">32651113</pub-id></mixed-citation></ref><ref id="b0575"><label>115</label><mixed-citation publication-type="other" id="h0575">Quinlan, B.D., Mou, H., Zhang, L., Guo, Y., He, W., Ojha, A., Parcells, M.S., Luo, G., Li, W., Zhong, G. and Choe, H., 2020. The SARS-CoV-2 receptor-binding domain elicits a potent neutralizing response without antibody-dependent enhancement.&#160;IMMUNITY-D-20-00389. doi:&#160;https://doi.org/10.1101/2020.04.10.036418.</mixed-citation></ref><ref id="b0580"><label>116</label><mixed-citation publication-type="other" id="h0580"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-sinovac-announce-collaboration-develop-coronavirus" id="ir015">http://investors.dynavax.com/news-releases/news-release-details/dynavax-and-sinovac-announce-collaboration-develop-coronavirus</ext-link> (01.00 PM on 01/05/2020).</mixed-citation></ref><ref id="b0585"><label>117</label><mixed-citation publication-type="other" id="h0585"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.gsk.com/en-gb/media/resource-centre/our-contribution-to-the-fight-against-2019-ncov/" id="ir020">https://www.gsk.com/en-gb/media/resource-centre/our-contribution-to-the-fight-against-2019-ncov/</ext-link> (01.00 PM on 01/05/2020).</mixed-citation></ref><ref id="b0590"><label>118</label><mixed-citation publication-type="other" id="h0590"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.bioworld.com/articles/433029-australia-ramps-up-efforts-to-fight-coronavirus-with-genetic-sequence-in-hand" id="ir025">https://www.bioworld.com/articles/433029-australia-ramps-up-efforts-to-fight-coronavirus-with-genetic-sequence-in-hand</ext-link> (01.00 PM on 01/05/2020).</mixed-citation></ref><ref id="b0595"><label>119</label><mixed-citation publication-type="other" id="h0595"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pipelinereview.com/index.php/2020040874282/Vaccines/Novavax-Identifies-Coronavirus-Vaccine-Candidate-Accelerates-Initiation-of-First-in-Human-Trial-to-Mid-May.html" id="ir030">https://pipelinereview.com/index.php/2020040874282/Vaccines/Novavax-Identifies-Coronavirus-Vaccine-Candidate-Accelerates-Initiation-of-First-in-Human-Trial-to-Mid-May.html</ext-link> (01.00 PM on 01/05/2020).</mixed-citation></ref><ref id="b0600"><label>120</label><mixed-citation publication-type="other" id="h0600"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.contractpharma.com/content-microsite/covid-19/2020-04-16/soligenix-licenses-btgs-covaccine-ht-for-sars-cov-2" id="ir035">https://www.contractpharma.com/content-microsite/covid-19/2020-04-16/soligenix-licenses-btgs-covaccine-ht-for-sars-cov-2</ext-link> (01.00 PM on 01/05/2020).</mixed-citation></ref><ref id="b0605"><label>121</label><element-citation publication-type="journal" id="h0605"><person-group person-group-type="author"><name name-style="western"><surname>Lakhan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Stevens</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Diener</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Hayball</surname><given-names>J.D.</given-names></name></person-group><article-title>CoVaccine HT&#8482; adjuvant is superior to Freund's adjuvants in eliciting antibodies against the endogenous alarmin HMGB1</article-title><source>J. Immunol. Methods</source><volume>439</volume><year>2016</year><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">27693642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jim.2016.09.008</pub-id></element-citation></ref><ref id="b0610"><label>122</label><element-citation publication-type="journal" id="h0610"><person-group person-group-type="author"><name name-style="western"><surname>Bodewes</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kreijtz</surname><given-names>J.H.C.M.</given-names></name><name name-style="western"><surname>van Amerongen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Geelhoed-Mieras</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Verburgh</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Heldens</surname><given-names>J.G.M.</given-names></name><name name-style="western"><surname>Bedwell</surname><given-names>J.</given-names></name><name name-style="western"><surname>van den Brand</surname><given-names>J.M.A.</given-names></name><name name-style="western"><surname>Kuiken</surname><given-names>T.</given-names></name><name name-style="western"><surname>van Baalen</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Fouchier</surname><given-names>R.A.M.</given-names></name></person-group><article-title>A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets</article-title><source>J. Virol.</source><volume>84</volume><issue>16</issue><year>2010</year><fpage>7943</fpage><lpage>7952</lpage><pub-id pub-id-type="pmid">20519384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.00549-10</pub-id><pub-id pub-id-type="pmcid">PMC2916550</pub-id></element-citation></ref><ref id="b0615"><label>123</label><mixed-citation publication-type="other" id="h0615"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.contractpharma.com/contents/view_breaking-news/2020-04-13/ibio-expands-covid-19-vaccine-collaboration/" id="ir040">https://www.contractpharma.com/contents/view_breaking-news/2020-04-13/ibio-expands-covid-19-vaccine-collaboration/</ext-link> (05.00 PM on 08/05/2020).</mixed-citation></ref><ref id="b0620"><label>124</label><element-citation publication-type="journal" id="h0620"><person-group person-group-type="author"><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Bertholet</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moutaftsi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guderian</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Windish</surname><given-names>H.P.</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Laughlin</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Duthie</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Friede</surname><given-names>M.</given-names></name></person-group><article-title>Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant</article-title><source>PLoS ONE</source><volume>6</volume><issue>1</issue><year>2011</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0016333</pub-id><pub-id pub-id-type="pmcid">PMC3027669</pub-id><pub-id pub-id-type="pmid">21298114</pub-id></element-citation></ref><ref id="b0625"><label>125</label><element-citation publication-type="journal" id="h0625"><person-group person-group-type="author"><name name-style="western"><surname>Schultze</surname><given-names>V.</given-names></name><name name-style="western"><surname>D&#8217;Agosto</surname><given-names>V.</given-names></name><name name-style="western"><surname>Wack</surname><given-names>A.</given-names></name><name name-style="western"><surname>Novicki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zorn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hennig</surname><given-names>R.</given-names></name></person-group><article-title>Safety of MF59&#8482; adjuvant</article-title><source>Vaccine</source><volume>26</volume><issue>26</issue><year>2008</year><fpage>3209</fpage><lpage>3222</lpage><pub-id pub-id-type="pmid">18462843</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.03.093</pub-id></element-citation></ref><ref id="b0630"><label>126</label><element-citation publication-type="journal" id="h0630"><person-group person-group-type="author"><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Comparative safety of vaccine adjuvants: a summary of current evidence and future needs</article-title><source>Drug Saf.</source><volume>38</volume><issue>11</issue><year>2015</year><fpage>1059</fpage><lpage>1074</lpage><pub-id pub-id-type="pmid">26446142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40264-015-0350-4</pub-id><pub-id pub-id-type="pmcid">PMC4615573</pub-id></element-citation></ref><ref id="b0635"><label>127</label><element-citation publication-type="journal" id="h0635"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Sajkov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Honda-Okubo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wilks</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Aban</surname><given-names>M.</given-names></name><name name-style="western"><surname>Barr</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax&#8482; delta inulin adjuvant</article-title><source>Vaccine</source><volume>34</volume><issue>33</issue><year>2016</year><fpage>3780</fpage><lpage>3786</lpage><pub-id pub-id-type="pmid">27342914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.05.071</pub-id><pub-id pub-id-type="pmcid">PMC4949042</pub-id></element-citation></ref><ref id="b0640"><label>128</label><element-citation publication-type="journal" id="h0640"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>P.</given-names></name><name name-style="western"><surname>Heinzel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>P.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Immunogenicity and safety of Advax&#8482;, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study</article-title><source>Vaccine</source><volume>32</volume><issue>48</issue><year>2014</year><fpage>6469</fpage><lpage>6477</lpage><pub-id pub-id-type="pmid">25267153</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2014.09.034</pub-id><pub-id pub-id-type="pmcid">PMC4253909</pub-id></element-citation></ref><ref id="b0645"><label>129</label><mixed-citation publication-type="other" id="h0645">Saxena, M., Sabado, R.L., LAMAR, M., Mohri, H., Salazar, A., Dong, H., Correa Da Rosa, J., Markowitz, M., Bhardwaj, N. and Miller, E., 2019. Poly-ICLC, a TLR3 agonist, induces transient Innate Immune Responses in Patients with Treated HIV-Infection: A Randomised Double-blinded Placebo Controlled Trial.&#160;Frontiers in immunology,&#160;10, p.725.<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.00725</pub-id><pub-id pub-id-type="pmcid">PMC6467168</pub-id><pub-id pub-id-type="pmid">31024557</pub-id></mixed-citation></ref><ref id="b0650"><label>130</label><element-citation publication-type="journal" id="h0650"><person-group person-group-type="author"><name name-style="western"><surname>Sabbatini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tsuji</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ferran</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sedrak</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tuballes</surname><given-names>K.</given-names></name><name name-style="western"><surname>Jungbluth</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ritter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Aghajanian</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bell-McGuinn</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hensley</surname><given-names>M.L.</given-names></name></person-group><article-title>Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients</article-title><source>Clin. Cancer Res.</source><volume>18</volume><issue>23</issue><year>2012</year><fpage>6497</fpage><lpage>6508</lpage><pub-id pub-id-type="pmid">23032745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/1078-0432.CCR-12-2189</pub-id></element-citation></ref><ref id="b0655"><label>131</label><element-citation publication-type="journal" id="h0655"><person-group person-group-type="author"><name name-style="western"><surname>Anwar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Shah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.</given-names></name><name name-style="western"><surname>Choi</surname><given-names>S.</given-names></name></person-group><article-title>Recent clinical trends in Toll-like receptor targeting therapeutics</article-title><source>Med. Res. Rev.</source><volume>39</volume><issue>3</issue><year>2019</year><fpage>1053</fpage><lpage>1090</lpage><pub-id pub-id-type="pmid">30450666</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/med.21553</pub-id><pub-id pub-id-type="pmcid">PMC6587958</pub-id></element-citation></ref><ref id="b0660"><label>132</label><element-citation publication-type="journal" id="h0660"><person-group person-group-type="author"><name name-style="western"><surname>Santini-Oliveira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Coler</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>Parra</surname><given-names>J.</given-names></name><name name-style="western"><surname>Veloso</surname><given-names>V.</given-names></name><name name-style="western"><surname>Jayashankar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pinto</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Ciol</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Bergquist</surname><given-names>R.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Tendler</surname><given-names>M.</given-names></name></person-group><article-title>Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adults</article-title><source>Vaccine</source><volume>34</volume><issue>4</issue><year>2016</year><fpage>586</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">26571311</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2015.10.027</pub-id></element-citation></ref><ref id="b0665"><label>133</label><element-citation publication-type="book" id="h0665"><person-group person-group-type="author"><name name-style="western"><surname>Shirota</surname><given-names>H.</given-names></name><name name-style="western"><surname>Klinman</surname><given-names>D.M.</given-names></name></person-group><chapter-title>CpG Oligodeoxynucleotides as adjuvants for clinical use. In <italic toggle="yes">Immunopotentiators in modern vaccines</italic></chapter-title><year>2017</year><publisher-name>Academic Press</publisher-name><fpage>163</fpage><lpage>198</lpage></element-citation></ref><ref id="b0670"><label>134</label><element-citation publication-type="journal" id="h0670"><person-group person-group-type="author"><name name-style="western"><surname>Pockros</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Guyader</surname><given-names>D.</given-names></name><name name-style="western"><surname>Patton</surname><given-names>H.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Wright</surname><given-names>T.</given-names></name><name name-style="western"><surname>McHutchison</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>T.C.</given-names></name></person-group><article-title>Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies</article-title><source>J. Hepatol.</source><volume>47</volume><issue>2</issue><year>2007</year><fpage>174</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">17532523</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jhep.2007.02.025</pub-id></element-citation></ref><ref id="b0675"><label>135</label><element-citation publication-type="journal" id="h0675"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Concannon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lustigman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Murasko</surname><given-names>D.M.</given-names></name></person-group><article-title>Enhanced humoral response to influenza vaccine in aged mice with a novel adjuvant, rOv-ASP-1</article-title><source>Vaccine</source><volume>34</volume><issue>7</issue><year>2016</year><fpage>887</fpage><lpage>892</lpage><pub-id pub-id-type="pmid">26795365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.01.003</pub-id><pub-id pub-id-type="pmcid">PMC4731280</pub-id></element-citation></ref><ref id="b0680"><label>136</label><element-citation publication-type="journal" id="h0680"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Reber</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Hoelscher</surname><given-names>M.</given-names></name><name name-style="western"><surname>Belser</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Katz</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Gangappa</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Sambhara</surname><given-names>S.</given-names></name></person-group><article-title>Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice</article-title><source>Vaccine</source><volume>35</volume><issue>25</issue><year>2017</year><fpage>3318</fpage><lpage>3325</lpage><pub-id pub-id-type="pmid">28499553</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.05.004</pub-id><pub-id pub-id-type="pmcid">PMC7115484</pub-id></element-citation></ref><ref id="b0685"><label>137</label><element-citation publication-type="journal" id="h0685"><person-group person-group-type="author"><name name-style="western"><surname>Chabot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brewer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lowell</surname><given-names>G.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cyr</surname><given-names>S.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>B.J.</given-names></name></person-group><article-title>A novel intranasal Protollin&#8482;-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice</article-title><source>Vaccine</source><volume>23</volume><issue>11</issue><year>2005</year><fpage>1374</fpage><lpage>1383</lpage><pub-id pub-id-type="pmid">15661386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2004.09.010</pub-id></element-citation></ref><ref id="b0690"><label>138</label><element-citation publication-type="journal" id="h0690"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cyr</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>R.</given-names></name></person-group><article-title>Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine</article-title><source>J. Clin. Virol.</source><volume>44</volume><issue>4</issue><year>2009</year><fpage>287</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">19233722</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jcv.2009.01.009</pub-id></element-citation></ref><ref id="b0695"><label>139</label><element-citation publication-type="journal" id="h0695"><person-group person-group-type="author"><name name-style="western"><surname>Kusi</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Remarque</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Riasat</surname><given-names>V.</given-names></name><name name-style="western"><surname>Walraven</surname><given-names>V.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>Faber</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Kocken</surname><given-names>C.H.</given-names></name></person-group><article-title>Safety and immunogenicity of multi-antigen AMA1-based vaccines formulated with CoVaccine HT&#8482; and Montanide ISA 51 in rhesus macaques</article-title><source>Malar. J.</source><volume>10</volume><issue>1</issue><year>2011</year><fpage>182</fpage><pub-id pub-id-type="pmid">21726452</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/1475-2875-10-182</pub-id><pub-id pub-id-type="pmcid">PMC3142537</pub-id></element-citation></ref><ref id="b0700"><label>140</label><element-citation publication-type="journal" id="h0700"><person-group person-group-type="author"><name name-style="western"><surname>Hamid</surname><given-names>M.M.A.</given-names></name><name name-style="western"><surname>Remarque</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>van Duivenvoorde</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>van der Werff</surname><given-names>N.</given-names></name><name name-style="western"><surname>Walraven</surname><given-names>V.</given-names></name><name name-style="western"><surname>Faber</surname><given-names>B.W.</given-names></name><name name-style="western"><surname>Kocken</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A.W.</given-names></name></person-group><article-title>Vaccination with Plasmodium knowlesi AMA1 formulated in the novel adjuvant co-vaccine HT&#8482; protects against blood-stage challenge in rhesus macaques</article-title><source>PLoS ONE</source><volume>6</volume><issue>5</issue><year>2011</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0020547</pub-id><pub-id pub-id-type="pmcid">PMC3105089</pub-id><pub-id pub-id-type="pmid">21655233</pub-id></element-citation></ref><ref id="b0705"><label>141</label><element-citation publication-type="journal" id="h0705"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Madhun</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Svindland</surname><given-names>S.</given-names></name><name name-style="western"><surname>S&#230;vik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Breakwell</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hoschler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Willemsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Campitelli</surname><given-names>L.</given-names></name><name name-style="western"><surname>N&#248;stbakken</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Weverling</surname><given-names>G.J.</given-names></name></person-group><article-title>Evaluation of a virosomal H5N1 vaccine formulated with Matrix M&#8482; adjuvant in a phase I clinical trial</article-title><source>Vaccine</source><volume>29</volume><issue>45</issue><year>2011</year><fpage>8049</fpage><lpage>8059</lpage><pub-id pub-id-type="pmid">21864624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2011.08.042</pub-id></element-citation></ref><ref id="b0710"><label>142</label><element-citation publication-type="journal" id="h0710"><person-group person-group-type="author"><name name-style="western"><surname>Pedersen</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Sjursen</surname><given-names>H.</given-names></name><name name-style="western"><surname>N&#248;stbakken</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Jul-Larsen</surname><given-names>&#197;.</given-names></name><name name-style="western"><surname>Hoschler</surname><given-names>K.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>R.J.</given-names></name></person-group><article-title>Matrix M<sup>TM</sup> adjuvanted virosomal H5N1 vaccine induces balanced Th1/Th2 CD4+ T cell responses in man</article-title><source>Human vaccines &amp; immunotherapeutics</source><volume>10</volume><issue>8</issue><year>2014</year><fpage>2408</fpage><lpage>2416</lpage><pub-id pub-id-type="pmid">25424948</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4161/hv.29583</pub-id><pub-id pub-id-type="pmcid">PMC4896793</pub-id></element-citation></ref><ref id="b0715"><label>143</label><element-citation publication-type="journal" id="h0715"><person-group person-group-type="author"><name name-style="western"><surname>Modjarrad</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>K.T.</given-names></name><name name-style="western"><surname>Castellano</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Paolino</surname><given-names>K.</given-names></name><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Robb</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Racine</surname><given-names>T.</given-names></name><name name-style="western"><surname>Oh</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Lamarre</surname><given-names>C.</given-names></name></person-group><article-title>Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial</article-title><source>Lancet. Infect. Dis</source><volume>19</volume><issue>9</issue><year>2019</year><fpage>1013</fpage><lpage>1022</lpage><pub-id pub-id-type="pmid">31351922</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(19)30266-X</pub-id><pub-id pub-id-type="pmcid">PMC7185789</pub-id></element-citation></ref><ref id="b0720"><label>144</label><element-citation publication-type="journal" id="h0720"><person-group person-group-type="author"><name name-style="western"><surname>Koch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Dahlke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fathi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kr&#228;hling</surname><given-names>V.</given-names></name><name name-style="western"><surname>Okba</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Halwe</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rohde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eickmann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Volz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hesterkamp</surname><given-names>T.</given-names></name></person-group><article-title>Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial</article-title><source>Lancet. Infect. Dis</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30248-6</pub-id><pub-id pub-id-type="pmcid">PMC7172913</pub-id><pub-id pub-id-type="pmid">32325037</pub-id></element-citation></ref><ref id="b0725"><label>145</label><element-citation publication-type="journal" id="h0725"><person-group person-group-type="author"><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Bittaye</surname><given-names>M.</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Bellamy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kupke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mair</surname><given-names>C.</given-names></name><name name-style="western"><surname>Makinson</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sheridan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rohde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Halwe</surname><given-names>S.</given-names></name></person-group><article-title>Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial</article-title><source>Lancet. Infect. Dis</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30160-2</pub-id><pub-id pub-id-type="pmcid">PMC7172901</pub-id><pub-id pub-id-type="pmid">32325038</pub-id></element-citation></ref><ref id="b0730"><label>146</label><element-citation publication-type="journal" id="h0730"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Louder</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Holman</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>I.J.</given-names></name><name name-style="western"><surname>Enama</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Larkin</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Koup</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Roederer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bailer</surname><given-names>R.T.</given-names></name></person-group><article-title>A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial</article-title><source>Vaccine</source><volume>26</volume><issue>50</issue><year>2008</year><fpage>6338</fpage><lpage>6343</lpage><pub-id pub-id-type="pmid">18824060</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2008.09.026</pub-id><pub-id pub-id-type="pmcid">PMC2612543</pub-id></element-citation></ref><ref id="b0735"><label>147</label><element-citation publication-type="journal" id="h0735"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Su</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>Y.P.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name></person-group><article-title>Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine</article-title><source>Antiviral therapy</source><volume>12</volume><issue>7</issue><year>2007</year><fpage>1107</fpage><pub-id pub-id-type="pmid">18018769</pub-id></element-citation></ref><ref id="b0740"><label>148</label><element-citation publication-type="journal" id="h0740"><person-group person-group-type="author"><name name-style="western"><surname>Jung</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.Y.</given-names></name><name name-style="western"><surname>Seo</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kwon</surname><given-names>T.</given-names></name><name name-style="western"><surname>Park</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Nam</surname><given-names>J.H.</given-names></name></person-group><article-title>Heterologous prime&#8211;boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus</article-title><source>Vaccine</source><volume>36</volume><issue>24</issue><year>2018</year><fpage>3468</fpage><lpage>3476</lpage><pub-id pub-id-type="pmid">29739720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2018.04.082</pub-id><pub-id pub-id-type="pmcid">PMC7115429</pub-id></element-citation></ref><ref id="b0745"><label>149</label><element-citation publication-type="journal" id="h0745"><person-group person-group-type="author"><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Fett</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>G.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Perlman</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Du</surname><given-names>L.</given-names></name></person-group><article-title>Recombinant receptor-binding domains of multiple Middle East respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants</article-title><source>J. Virol.</source><volume>91</volume><issue>1</issue><year>2017</year><fpage>e01651</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">27795425</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01651-16</pub-id><pub-id pub-id-type="pmcid">PMC5165220</pub-id></element-citation></ref><ref id="b0750"><label>150</label><element-citation publication-type="journal" id="h0750"><person-group person-group-type="author"><name name-style="western"><surname>Coleman</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Venkataraman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.V.</given-names></name><name name-style="western"><surname>Glenn</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Flyer</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Frieman</surname><given-names>M.B.</given-names></name></person-group><article-title>MERS-CoV spike nanoparticles protect mice from MERS-CoV infection</article-title><source>Vaccine</source><volume>35</volume><issue>12</issue><year>2017</year><fpage>1586</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">28237499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2017.02.012</pub-id><pub-id pub-id-type="pmcid">PMC5423355</pub-id></element-citation></ref><ref id="b0755"><label>151</label><mixed-citation publication-type="other" id="h0755"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines" id="ir045">https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines</ext-link>.</mixed-citation></ref><ref id="b0760"><label>152</label><element-citation publication-type="journal" id="h0760"><person-group person-group-type="author"><name name-style="western"><surname>Ghimire</surname><given-names>T.R.</given-names></name></person-group><article-title>The mechanisms of action of vaccines containing aluminum adjuvants: an in vitro vs in vivo paradigm</article-title><source>Springerplus</source><volume>4</volume><issue>1</issue><year>2015</year><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">25932368</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40064-015-0972-0</pub-id><pub-id pub-id-type="pmcid">PMC4406982</pub-id></element-citation></ref><ref id="b0765"><label>153</label><element-citation publication-type="journal" id="h0765"><person-group person-group-type="author"><name name-style="western"><surname>Fu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name></person-group><article-title>Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools</article-title><source>Virologica Sinica</source><year>2020</year><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">32125642</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12250-020-00207-4</pub-id><pub-id pub-id-type="pmcid">PMC7090474</pub-id></element-citation></ref><ref id="b0770"><label>154</label><mixed-citation publication-type="other" id="h0770">Wu, D. and Yang, X.O., 2020. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib.&#160;Journal of Microbiology, Immunology and Infection.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmii.2020.03.005</pub-id><pub-id pub-id-type="pmcid">PMC7156211</pub-id><pub-id pub-id-type="pmid">32205092</pub-id></mixed-citation></ref><ref id="b0775"><label>155</label><element-citation publication-type="journal" id="h0775"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name></person-group><article-title>COVID-19: immunopathology and its implications for therapy</article-title><source>Nat. Rev. Immunol.</source><volume>20</volume><issue>5</issue><year>2020</year><fpage>269</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">32273594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0308-3</pub-id><pub-id pub-id-type="pmcid">PMC7143200</pub-id></element-citation></ref><ref id="b0780"><label>156</label><element-citation publication-type="journal" id="h0780"><person-group person-group-type="author"><name name-style="western"><surname>Takada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kawaoka</surname><given-names>Y.</given-names></name></person-group><article-title>Antibody-dependent enhancement of viral infection: molecular mechanisms and in vivo implications</article-title><source>Rev. Med. Virol.</source><volume>13</volume><issue>6</issue><year>2003</year><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">14625886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/rmv.405</pub-id></element-citation></ref><ref id="b0785"><label>157</label><element-citation publication-type="journal" id="h0785"><person-group person-group-type="author"><name name-style="western"><surname>Tirado</surname><given-names>S.M.C.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>K.J.</given-names></name></person-group><article-title>Antibody-dependent enhancement of virus infection and disease</article-title><source>Viral Immunol.</source><volume>16</volume><issue>1</issue><year>2003</year><fpage>69</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">12725690</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/088282403763635465</pub-id></element-citation></ref><ref id="b0790"><label>158</label><element-citation publication-type="journal" id="h0790"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S.F.</given-names></name><name name-style="western"><surname>Tseng</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Yen</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Tsao</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.M.A.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.C.</given-names></name></person-group><article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title><source>Biochem. Biophys. Res. Commun.</source><volume>451</volume><issue>2</issue><year>2014</year><fpage>208</fpage><lpage>214</lpage><pub-id pub-id-type="pmid">25073113</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbrc.2014.07.090</pub-id><pub-id pub-id-type="pmcid">PMC7092860</pub-id></element-citation></ref><ref id="b0795"><label>159</label><element-citation publication-type="journal" id="h0795"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Shang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>He</surname><given-names>L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name></person-group><article-title>Molecular mechanism for antibody-dependent enhancement of coronavirus entry</article-title><source>J. Virol.</source><volume>94</volume><issue>5</issue><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.02015-19</pub-id><pub-id pub-id-type="pmcid">PMC7022351</pub-id><pub-id pub-id-type="pmid">31826992</pub-id></element-citation></ref><ref id="b0800"><label>160</label><element-citation publication-type="journal" id="h0800"><person-group person-group-type="author"><name name-style="western"><surname>Tetro</surname><given-names>J.A.</given-names></name></person-group><article-title>Is COVID-19 receiving ADE from other coronaviruses?</article-title><source>Microbes Infect.</source><volume>22</volume><issue>2</issue><year>2020</year><fpage>72</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">32092539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2020.02.006</pub-id><pub-id pub-id-type="pmcid">PMC7102551</pub-id></element-citation></ref><ref id="b0805"><label>161</label><mixed-citation publication-type="other" id="h0805">van Doremalen, N., Lambe, T., Spencer, A., Belij-Rammerstorfer, S., Purushotham, J., Port, J., Avanzato, V., Bushmaker, T., Flaxman, A., Ulaszewska, M. and Feldmann, F., 2020. ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques.&#160;bioRxiv.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2608-y</pub-id><pub-id pub-id-type="pmcid">PMC8436420</pub-id><pub-id pub-id-type="pmid">32731258</pub-id></mixed-citation></ref><ref id="b0810"><label>162</label><element-citation publication-type="journal" id="h0810"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Elwood</surname><given-names>D.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gary</surname><given-names>E.N.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Schultheis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Purwar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name></person-group><article-title>Immunogenicity of a DNA vaccine candidate for COVID-19</article-title><source>Nat. Commun.</source><volume>11</volume><issue>1</issue><year>2020</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">32433465</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-16505-0</pub-id><pub-id pub-id-type="pmcid">PMC7239918</pub-id></element-citation></ref><ref id="b0815"><label>163</label><mixed-citation publication-type="other" id="h0815">Yu, J., Tostanoski, L.H., Peter, L., Mercado, N.B., McMahan, K., Mahrokhian, S.H., Nkolola, J.P., Liu, J., Li, Z., Chandrashekar, A. and Martinez, D.R., 2020. DNA vaccine protection against SARS-CoV-2 in rhesus macaques.&#160;Science.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc6284</pub-id><pub-id pub-id-type="pmcid">PMC7243363</pub-id><pub-id pub-id-type="pmid">32434945</pub-id></mixed-citation></ref><ref id="b0820"><label>164</label><element-citation publication-type="journal" id="h0820"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F.C.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Guan</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>L.H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>S.Y.</given-names></name></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial</article-title><source>The Lancet</source><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)31208-3</pub-id><pub-id pub-id-type="pmcid">PMC7255193</pub-id><pub-id pub-id-type="pmid">32450106</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>